Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:difluorobenzene
go back to main search page
Accession:CHEBI:38582 term browser browse the term
Definition:Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying two fluorine atoms.
Synonyms:related_synonym: Difluorbenzol;   Formula=C6H4F2;   difluorobenzenes


show annotations for term's descendants           Sort by:
 
cobimetinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2l11 BCL2 like 11 increases expression
multiple interactions
ISO cobimetinib results in increased expression of BCL2L11 protein; cobimetinib results in increased expression of BCL2L11 protein alternative form
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein alternative form]; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with cobimetinib] results in decreased phosphorylation of BCL2L11 protein alternative form; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form]
CTD PMID:22084396 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
increases response to substance
ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [BRAF protein mutant form results in increased susceptibility to cobimetinib] CTD PMID:22084396 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO cobimetinib results in decreased expression of CCND1 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in decreased expression of CCND1 protein]
CTD PMID:22084396 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion EXP cobimetinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Kras KRAS proto-oncogene, GTPase increases response to substance
multiple interactions
ISO KRAS protein mutant form results in increased susceptibility to cobimetinib
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [KRAS protein mutant form results in increased susceptibility to cobimetinib]; cobimetinib promotes the reaction [KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]
CTD PMID:22084396 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO cobimetinib results in decreased phosphorylation of MAPK1 protein CTD PMID:22084396 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO cobimetinib results in decreased phosphorylation of MAPK3 protein CTD PMID:22084396 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Nras NRAS proto-oncogene, GTPase increases response to substance ISO NRAS protein mutant form results in increased susceptibility to cobimetinib CTD PMID:22084396 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased cleavage of PARP1 protein]; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased cleavage of PARP1 protein] CTD PMID:22084396 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein] CTD PMID:22084396 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
DAPT term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]] CTD PMID:31348943 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein] CTD PMID:31348943 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G App amyloid beta precursor protein multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form] CTD PMID:22115781 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein CTD PMID:21209419 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein CTD PMID:21209419 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA] CTD PMID:23566955 NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
JBrowse link
G Casp3 caspase 3 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein CTD PMID:21209419 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] CTD PMID:19160421 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein] CTD PMID:18791180 PMID:31348943 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh2 cadherin 2 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein] CTD PMID:23876460 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA] CTD PMID:24223152 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
JBrowse link
G Eno2 enolase 2 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA] CTD PMID:24929042 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein] CTD PMID:21843347 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein] CTD PMID:25108166 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Hes1 hes family bHLH transcription factor 1 multiple interactions
decreases expression
ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein
CTD PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
JBrowse link
G Hey1 hes-related family bHLH transcription factor with YRPW motif 1 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] CTD PMID:19160421 NCBI chr 2:95,320,147...95,322,701
Ensembl chr 2:95,320,283...95,322,696
JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA]
CTD PMID:19160421 PMID:32041402 NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] CTD PMID:25108166 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein] CTD PMID:21843347 NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
JBrowse link
G Il10 interleukin 10 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA] CTD PMID:24223152 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA]
CTD PMID:21843347 PMID:24223152 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions EXP
ISO
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]
CTD PMID:21843347 PMID:24223152 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein] CTD PMID:28130038 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Ivl involucrin decreases expression ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein CTD PMID:18633435 NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
JBrowse link
G Jag1 jagged canonical Notch ligand 1 decreases expression ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein CTD PMID:18633435 NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
JBrowse link
G Krt1 keratin 1 multiple interactions
decreases expression
ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA
CTD PMID:18633435 PMID:23566955 NCBI chr 7:143,448,318...143,453,544
Ensembl chr 7:143,448,318...143,453,544
JBrowse link
G Krt10 keratin 10 multiple interactions
decreases expression
ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein
CTD PMID:18633435 PMID:23566955 NCBI chr10:87,296,445...87,301,307
Ensembl chr10:87,296,451...87,300,736
JBrowse link
G Lgr5 leucine rich repeat containing G protein coupled receptor 5 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA] CTD PMID:32041402 NCBI chr 7:58,447,097...58,587,787
Ensembl chr 7:58,448,277...58,587,787
JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA] CTD PMID:24929042 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases expression
ISO Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein] CTD PMID:25005833 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA]
CTD PMID:24223152 NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA]
CTD PMID:24223152 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Notch1 notch receptor 1 multiple interactions
decreases expression
ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form
CTD PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 PMID:25118938 PMID:28130038 PMID:31348943 NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
JBrowse link
G Notch2 notch receptor 2 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein CTD PMID:22039516 NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
JBrowse link
G Numb NUMB, endocytic adaptor protein increases expression ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein CTD PMID:25005833 NCBI chr 6:107,279,917...107,325,345
Ensembl chr 6:107,279,920...107,325,345
JBrowse link
G Pml PML nuclear body scaffold multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] CTD PMID:28130038 NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA] CTD PMID:18791180 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] CTD PMID:28130038 NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
JBrowse link
G Rbpj recombination signal binding protein for immunoglobulin kappa J region multiple interactions
increases expression
EXP
ISO
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]
CTD PMID:22302987 PMID:24223152 NCBI chr14:59,657,738...59,865,427
Ensembl chr14:59,658,935...59,735,450
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein] CTD PMID:24223152 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA] CTD PMID:24223152 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA] CTD PMID:24223152 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]
CTD PMID:24223152 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 decreases expression
multiple interactions
ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein]
CTD PMID:25005833 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO
EXP
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein]
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA]
CTD PMID:24223152 NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA] CTD PMID:24929042 NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] CTD PMID:21843347 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vil1 villin 1 multiple interactions EXP N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA] CTD PMID:32041402 NCBI chr 9:81,689,802...81,717,623
Ensembl chr 9:81,689,802...81,717,621
JBrowse link
diflubenzuron term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression EXP Diflubenzuron results in increased expression of CYP1A1 protein CTD PMID:8812189 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects binding ISO Diflubenzuron binds to CYP1A2 protein CTD PMID:32278787 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 increases expression EXP Diflubenzuron results in increased expression of CYP3A23-3A1 protein CTD PMID:8812189 NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 affects binding ISO Diflubenzuron binds to CYP3A4 protein CTD PMID:32278787 NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases activity ISO Diflubenzuron results in increased activity of NR1I2 protein CTD PMID:16565514 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
diflunisal term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression ISO Diflunisal results in increased expression of FOS mRNA CTD PMID:12730611 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Il1b interleukin 1 beta increases expression EXP Diflunisal results in increased expression of IL1B mRNA CTD PMID:15135310 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 increases expression EXP Diflunisal results in increased expression of IL6 mRNA CTD PMID:15135310 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G LOC100364500 RT1 class I, locus CE11-like affects expression ISO Diflunisal affects the expression of HLA-A mRNA CTD PMID:25811541 NCBI chr20:2,704,153...2,707,111
Ensembl chr20:2,704,148...2,707,120
JBrowse link
G Nos2 nitric oxide synthase 2 increases expression EXP Diflunisal results in increased expression of NOS2 mRNA CTD PMID:15135310 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Tnf tumor necrosis factor increases expression EXP Diflunisal results in increased expression of TNF mRNA CTD PMID:15135310 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Ttr transthyretin affects binding
multiple interactions
ISO Diflunisal binds to TTR protein mutant form
[Diflunisal binds to TTR protein mutant form] which results in decreased susceptibility to Urea; Diflunisal results in increased stability of [TTR protein binds to TTR protein binds to TTR protein binds to TTR protein]
CTD PMID:17701470 PMID:27093678 NCBI chr18:15,532,963...15,542,180
Ensembl chr18:15,532,963...15,540,177
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases activity ISO Diflunisal results in decreased activity of UGT1A1 protein CTD PMID:15593333 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 increases glucuronidation ISO UGT1A3 protein results in increased glucuronidation of Diflunisal CTD PMID:15117964 NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a8 UDP glucuronosyltransferase family 1 member A8 increases glucuronidation ISO UGT1A8 protein results in increased glucuronidation of Diflunisal CTD PMID:15117964 NCBI chr 9:95,221,474...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 multiple interactions
increases glucuronidation
ISO Diflunisal inhibits the reaction [UGT2B7 protein results in increased chemical synthesis of aldosterone 18-glucuronide]; Diflunisal inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]
UGT2B7 protein alternative form results in increased glucuronidation of Diflunisal; UGT2B7 protein results in increased glucuronidation of Diflunisal
CTD PMID:8423545 PMID:8517101 PMID:19740398 NCBI chr14:22,597,103...22,619,968 JBrowse link
fluconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb9 ATP binding cassette subfamily B member 9 decreases expression EXP Fluconazole results in decreased expression of ABCB9 mRNA CTD PMID:16643972 NCBI chr12:37,923,974...37,956,678
Ensembl chr12:37,923,528...37,958,363
JBrowse link
G Adh1 alcohol dehydrogenase 1 (class I) decreases expression EXP Fluconazole results in decreased expression of ADH1 mRNA CTD PMID:16643972 NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 increases expression EXP Fluconazole results in increased expression of AKR7A3 mRNA CTD PMID:16643972 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Apoa4 apolipoprotein A4 decreases expression EXP Fluconazole results in decreased expression of APOA4 mRNA CTD PMID:16643972 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G Ces2h carboxylesterase 2H increases expression EXP Fluconazole results in increased expression of CES2 mRNA CTD PMID:16643972 NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 affects activity ISO Fluconazole affects the activity of CYP17A1 protein CTD PMID:31330226 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions
decreases activity
ISO [Fluconazole results in decreased activity of CYP19A1 protein] which results in decreased chemical synthesis of Estrone; [Fluconazole results in decreased activity of CYP19A1 protein] which results in decreased metabolism of Androstenedione CTD PMID:31330226 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases expression ISO Fluconazole results in increased expression of CYP1A2 mRNA CTD PMID:16730040 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression ISO Fluconazole results in increased expression of CYP26A1 mRNA CTD PMID:19429397 NCBI chr 1:256,382,861...256,386,729
Ensembl chr 1:256,382,791...256,386,729
JBrowse link
G Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 increases expression ISO Fluconazole results in increased expression of CYP26B1 mRNA CTD PMID:19429397 NCBI chr 4:116,261,796...116,278,615
Ensembl chr 4:116,261,796...116,278,615
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions
increases expression
ISO NR1I3 promotes the reaction [Fluconazole results in increased expression of CYP2B10 mRNA] CTD PMID:16730040 PMID:25656644 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases expression EXP Fluconazole results in decreased expression of CYP2C mRNA CTD PMID:16643972 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp2c24 cytochrome P450, family 2, subfamily c, polypeptide 24 increases expression ISO Fluconazole results in increased expression of CYP2C55 mRNA CTD PMID:16730040 NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 decreases activity
multiple interactions
increases metabolic processing
ISO Fluconazole results in decreased activity of CYP2C19 protein
[Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole
CYP2C19 protein results in increased metabolism of Fluconazole
CTD PMID:12464242 PMID:15843491 PMID:17702393 PMID:19328226 PMID:26599973 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases expression ISO Fluconazole results in increased expression of CYP2C29 mRNA CTD PMID:16730040 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2g1 cytochrome P450, family 2, subfamily g, polypeptide 1 decreases expression EXP Fluconazole results in decreased expression of CYP2G1 mRNA CTD PMID:16643972 NCBI chr 1:83,626,639...83,638,154
Ensembl chr 1:83,626,639...83,637,780
JBrowse link
G Cyp2j4 cytochrome P450, family 2, subfamily j, polypeptide 4 decreases expression ISO Fluconazole results in decreased expression of CYP2J9 mRNA CTD PMID:16730040 NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 increases expression
affects expression
EXP Fluconazole results in increased expression of CYP3A23-3A1 mRNA
Fluconazole affects the expression of CYP3A23-3A1 mRNA
CTD PMID:16643972 PMID:20623750 NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 decreases activity ISO Fluconazole results in decreased activity of CYP3A4 protein CTD PMID:15784650 PMID:15843491 NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases expression EXP Fluconazole results in increased expression of CYP3A13 mRNA CTD PMID:16643972 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Cyp51 cytochrome P450, family 51 decreases activity
decreases response to substance
multiple interactions
ISO Fluconazole results in decreased activity of CYP51A1 protein
CYP51A1 gene results in decreased susceptibility to Fluconazole
CYP51A1 gene inhibits the reaction [Fluconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Fluconazole results in decreased metabolism of and results in increased abundance of 14-methylergosta-8,24(28)-dien-3,6-diol]; CYP51A1 gene inhibits the reaction [Fluconazole results in decreased metabolism of and results in increased abundance of Lanosterol]
CTD PMID:16989930 PMID:18694951 NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
JBrowse link
G Gstm1 glutathione S-transferase mu 1 increases expression ISO Fluconazole results in increased expression of GSTM1 mRNA CTD PMID:16730040 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit decreases expression EXP Fluconazole results in decreased expression of JUND mRNA CTD PMID:16643972 NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
JBrowse link
G Lcn2 lipocalin 2 increases expression EXP Fluconazole results in increased expression of LCN2 mRNA CTD PMID:20623750 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Mark2 microtubule affinity regulating kinase 2 increases expression ISO Fluconazole results in increased expression of MARK2 mRNA CTD PMID:16730040 NCBI chr 1:222,525,547...222,590,727
Ensembl chr 1:222,525,990...222,590,220
JBrowse link
G Mpo myeloperoxidase increases expression EXP Fluconazole results in increased expression of MPO mRNA CTD PMID:20623750 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] CTD PMID:17438109 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 affects response to substance
increases response to substance
multiple interactions
ISO NR1I3 protein affects the susceptibility to Fluconazole
NR1I3 results in increased susceptibility to Fluconazole
NR1I3 promotes the reaction [Fluconazole results in increased expression of CYP2B10 mRNA]; NR1I3 promotes the reaction [Fluconazole results in increased expression of CYP3A11 mRNA]; NR1I3 promotes the reaction [Fluconazole results in increased expression of POR mRNA]
CTD PMID:23721867 PMID:25656644 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Por cytochrome p450 oxidoreductase decreases expression
multiple interactions
increases expression
EXP
ISO
Fluconazole results in decreased expression of POR mRNA
NR1I3 promotes the reaction [Fluconazole results in increased expression of POR mRNA]
CTD PMID:16643972 PMID:16730040 PMID:25656644 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression EXP Fluconazole results in increased expression of PPARG mRNA CTD PMID:20623750 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Slc13a2 solute carrier family 13 member 2 decreases expression ISO Fluconazole results in decreased expression of SLC13A2 mRNA CTD PMID:16730040 NCBI chr10:65,664,665...65,692,046
Ensembl chr10:65,664,667...65,692,023
JBrowse link
G Slc6a13 solute carrier family 6 member 13 decreases expression EXP Fluconazole results in decreased expression of SLC6A13 mRNA CTD PMID:16643972 NCBI chr 4:153,874,942...153,912,185
Ensembl chr 4:153,874,852...153,912,155
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO Fluconazole results in increased expression of SLCO1A4 mRNA CTD PMID:16730040 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Srd5a1 steroid 5 alpha-reductase 1 decreases expression EXP Fluconazole results in decreased expression of SRD5A1 mRNA CTD PMID:16643972 NCBI chr 1:36,320,504...36,354,694
Ensembl chr 1:36,320,461...36,354,756
JBrowse link
G Star steroidogenic acute regulatory protein increases expression ISO Fluconazole results in increased expression of STAR mRNA CTD PMID:23038793 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 affects expression EXP Fluconazole affects the expression of UGT1A9 mRNA CTD PMID:20623750 NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b17 UDP glucuronosyltransferase family 2 member B17 increases expression EXP Fluconazole results in increased expression of UGT2B1 mRNA CTD PMID:16643972 NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 multiple interactions ISO Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol] CTD PMID:18098064 NCBI chr14:22,597,103...22,619,968 JBrowse link
PD 0325901 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adam19 ADAM metallopeptidase domain 19 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of ADAM19 mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of ADAM19 mRNA
CTD PMID:25119042 NCBI chr10:31,146,107...31,240,582
Ensembl chr10:31,146,107...31,240,582
JBrowse link
G Adamts6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of ADAMTS6 mRNA CTD PMID:25119042 NCBI chr 2:34,374,142...34,589,676
Ensembl chr 2:34,374,158...34,586,755
JBrowse link
G Akap12 A-kinase anchoring protein 12 decreases expression ISO PD 0325901 results in decreased expression of AKAP12 mRNA CTD PMID:25119042 NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
ISO [PD 0325901 co-treated with MK 2206] results in increased phosphorylation of AKT1 protein; [PD 0325901 co-treated with silmitasertib] results in decreased phosphorylation of AKT1 protein; PD 0325901 promotes the reaction [dactolisib results in decreased phosphorylation of AKT1 protein]; romidepsin inhibits the reaction [[PD 0325901 co-treated with MK 2206] results in increased phosphorylation of AKT1 protein]
PD 0325901 results in increased phosphorylation of AKT1 protein
CTD PMID:22415236 PMID:25798061 PMID:27634878 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alb albumin decreases expression EXP PD 0325901 results in decreased expression of ALB protein CTD PMID:21976371 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Ank3 ankyrin 3 multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of ANK3 mRNA CTD PMID:25119042 NCBI chr20:19,948,767...20,480,628
Ensembl chr20:20,105,047...20,480,623
JBrowse link
G Ano1 anoctamin 1 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of ANO1 mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of ANO1 mRNA
CTD PMID:25119042 NCBI chr 1:217,754,349...217,902,540
Ensembl chr 1:217,754,336...217,902,473
JBrowse link
G Anpep alanyl aminopeptidase, membrane decreases expression ISO PD 0325901 results in decreased expression of ANPEP mRNA CTD PMID:25119042 NCBI chr 1:141,561,364...141,604,249
Ensembl chr 1:141,561,334...141,604,273
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of ARHGAP24 mRNA CTD PMID:25119042 NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512
JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO PD 0325901 results in decreased expression of ARL4C mRNA CTD PMID:25119042 NCBI chr 9:95,783,651...95,787,092
Ensembl chr 9:95,786,508...95,787,094
JBrowse link
G Bak1 BCL2-antagonist/killer 1 increases expression
multiple interactions
ISO PD 0325901 results in increased expression of BAK1 protein
[PD 0325901 co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with PD 0325901 co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with PD 0325901] results in increased expression of BAK1 protein
CTD PMID:27634878 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [PD 0325901 co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with PD 0325901 co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with PD 0325901] results in increased expression of BCL2L11 protein; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [PD 0325901 results in increased expression of BCL2L11 protein]]; KRAS protein affects the reaction [PD 0325901 results in increased expression of BCL2L11 protein]; NVP-BKM120 promotes the reaction [PD 0325901 results in increased expression of BCL2L11 protein] CTD PMID:24576621 PMID:27634878 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [PD 0325901 co-treated with MK 2206] results in increased expression of BID mRNA; [PD 0325901 co-treated with MK 2206] results in increased expression of BID protein modified form CTD PMID:28691888 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of BIRC3 mRNA CTD PMID:25119042 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of CCL20 mRNA
PD 0325901 results in decreased expression of CCL20 mRNA
CTD PMID:25119042 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO PD 0325901 inhibits the reaction [camostat results in increased expression of CCND1 protein] CTD PMID:25104499 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 multiple interactions ISO PD 0325901 inhibits the reaction [camostat results in increased expression of CCND3 protein] CTD PMID:25104499 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO PD 0325901 inhibits the reaction [camostat results in increased expression of CCNE1 protein] CTD PMID:25104499 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
PD 0325901 results in decreased expression of CXCL1 mRNA
CTD PMID:25119042 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
PD 0325901 results in decreased expression of CXCL1 mRNA
CTD PMID:25119042 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cyb5r2 cytochrome b5 reductase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of CYB5R2 mRNA
PD 0325901 results in decreased expression of CYB5R2 mRNA
CTD PMID:25119042 NCBI chr 1:171,971,424...171,981,586
Ensembl chr 1:171,971,701...171,979,933
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 decreases expression
increases expression
EXP PD 0325901 results in decreased expression of CYP24A1 mRNA
PD 0325901 results in increased expression of CYP24A1 mRNA
CTD PMID:21976371 PMID:23872713 NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
JBrowse link
G Cyp27b1 cytochrome P450, family 27, subfamily b, polypeptide 1 increases expression EXP PD 0325901 results in increased expression of CYP27B1 mRNA CTD PMID:21976371 NCBI chr 7:70,333,150...70,340,006
Ensembl chr 7:70,335,061...70,340,005
JBrowse link
G Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 increases expression ISO PD 0325901 results in increased expression of CYP3A4 mRNA CTD PMID:24819614 NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases expression ISO PD 0325901 results in increased expression of CYP3A5 mRNA CTD PMID:24819614 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Dcbld2 discoidin, CUB and LCCL domain containing 2 decreases expression ISO PD 0325901 results in decreased expression of DCBLD2 mRNA CTD PMID:25119042 NCBI chr11:44,237,814...44,292,884
Ensembl chr11:44,241,111...44,292,884
JBrowse link
G Dnmbp dynamin binding protein decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of DNMBP mRNA
[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of DNMBP mRNA
CTD PMID:25119042 NCBI chr 1:263,625,503...263,718,784
Ensembl chr 1:263,625,501...263,718,745
JBrowse link
G Dock4 dedicator of cytokinesis 4 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of DOCK4 mRNA
PD 0325901 results in decreased expression of DOCK4 mRNA
CTD PMID:25119042 NCBI chr 6:60,374,839...60,782,648
Ensembl chr 6:60,566,196...60,782,556
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of DUSP4 mRNA
[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of DUSP4 mRNA
CTD PMID:25119042 NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169
JBrowse link
G Dusp6 dual specificity phosphatase 6 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of DUSP6 mRNA
PD 0325901 results in decreased expression of DUSP6 mRNA
CTD PMID:25119042 NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
JBrowse link
G Efna5 ephrin A5 multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of EFNA5 mRNA CTD PMID:25119042 NCBI chr 9:110,054,002...110,329,878
Ensembl chr 9:110,057,155...110,225,486
JBrowse link
G Egr1 early growth response 1 decreases expression
multiple interactions
EXP
ISO
PD 0325901 results in decreased expression of EGR1 mRNA
PD 0325901 inhibits the reaction [camostat results in increased expression of EGR1 mRNA]
CTD PMID:21976371 PMID:25104499 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [Ku 0063794 co-treated with PD 0325901] results in decreased phosphorylation of EIF4EBP1 protein; PD 0325901 promotes the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:22415236 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Emp1 epithelial membrane protein 1 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of EMP1 mRNA
PD 0325901 results in decreased expression of EMP1 mRNA
CTD PMID:25119042 NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression
ISO PD 0325901 inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]; PD 0325901 inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]
PD 0325901 results in decreased expression of ERCC1 mRNA
CTD PMID:21996734 NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases expression ISO PD 0325901 results in increased expression of ERCC4 mRNA CTD PMID:21996734 NCBI chr10:2,010,140...2,037,953
Ensembl chr10:2,010,648...2,037,891
JBrowse link
G Esm1 endothelial cell-specific molecule 1 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ESM1 mRNA
PD 0325901 results in decreased expression of ESM1 mRNA
CTD PMID:25119042 NCBI chr 2:45,104,392...45,113,130
Ensembl chr 2:45,104,305...45,113,131
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ETS1 mRNA CTD PMID:25119042 NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
JBrowse link
G Etv1 ETS variant transcription factor 1 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ETV1 mRNA
PD 0325901 results in decreased expression of ETV1 mRNA
CTD PMID:25119042 NCBI chr 6:58,467,215...58,558,640
Ensembl chr 6:58,467,254...58,558,631
JBrowse link
G Etv4 ETS variant transcription factor 4 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ETV4 mRNA
PD 0325901 results in decreased expression of ETV4 mRNA
CTD PMID:25119042 NCBI chr10:89,685,058...89,700,300
Ensembl chr10:89,685,058...89,700,283
JBrowse link
G Etv5 ETS variant transcription factor 5 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ETV5 mRNA
PD 0325901 results in decreased expression of ETV5 mRNA
CTD PMID:25119042 NCBI chr11:82,194,657...82,252,145
Ensembl chr11:82,194,657...82,252,139
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO PD 0325901 inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]] CTD PMID:26670611 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fgf23 fibroblast growth factor 23 multiple interactions EXP PD 0325901 inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]; PD 0325901 inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]; PD 0325901 results in increased expression of and results in increased secretion of FGF23 protein CTD PMID:23872713 NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
JBrowse link
G Fmnl2 formin-like 2 decreases expression ISO PD 0325901 results in decreased expression of FMNL2 mRNA CTD PMID:25119042 NCBI chr 3:38,400,409...38,677,637
Ensembl chr 3:38,559,914...38,675,878
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression
multiple interactions
EXP
ISO
PD 0325901 results in decreased expression of FOS mRNA
PD 0325901 inhibits the reaction [camostat results in increased expression of FOS mRNA]
CTD PMID:21976371 PMID:25104499 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of FOSL1 protein
[PD 0325901 co-treated with silmitasertib] results in decreased expression of FOSL1 protein
CTD PMID:25798061 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
JBrowse link
G Foxg1 forkhead box G1 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of FOXG1 mRNA
[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of FOXG1 mRNA
CTD PMID:25119042 NCBI chr 6:69,971,227...69,974,037
Ensembl chr 6:69,971,227...69,974,037
JBrowse link
G Foxo3 forkhead box O3 increases expression
multiple interactions
ISO PD 0325901 results in increased expression of FOXO3 protein
PD 0325901 inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; PD 0325901 promotes the reaction [Luteolin results in increased expression of FOXO3 protein]
CTD PMID:32268164 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Glrx glutaredoxin multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of GLRX mRNA
PD 0325901 results in decreased expression of GLRX mRNA
CTD PMID:25119042 NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
JBrowse link
G Gypc glycophorin C (Gerbich blood group) multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of GYPC mRNA
PD 0325901 results in decreased expression of GYPC mRNA
CTD PMID:25119042 NCBI chr18:25,312,386...25,344,614
Ensembl chr18:25,312,387...25,344,614
JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of HAS2 mRNA
PD 0325901 results in decreased expression of HAS2 mRNA
CTD PMID:25119042 NCBI chr 7:96,438,046...96,464,049
Ensembl chr 7:96,438,046...96,464,049
JBrowse link
G Hdac9 histone deacetylase 9 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of HDAC9 mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of HDAC9 mRNA
CTD PMID:25119042 NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119
JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of HSD17B2 mRNA
PD 0325901 results in decreased expression of HSD17B2 mRNA
CTD PMID:25119042 NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of HTR7 mRNA
PD 0325901 results in decreased expression of HTR7 mRNA
CTD PMID:25119042 NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
JBrowse link
G Ifng interferon gamma multiple interactions ISO PD 0325901 inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; PD 0325901 inhibits the reaction [IL15 protein results in increased secretion of IFNG protein]; PD 0325901 inhibits the reaction [IL2 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of IGFBP3 mRNA CTD PMID:25119042 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
JBrowse link
G Il15 interleukin 15 multiple interactions ISO PD 0325901 inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; PD 0325901 inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; PD 0325901 inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; PD 0325901 inhibits the reaction [IL15 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
JBrowse link
G Il18 interleukin 18 multiple interactions ISO PD 0325901 inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of IL1B mRNA
PD 0325901 results in decreased expression of IL1B mRNA
CTD PMID:25119042 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of IL1RAPL1 mRNA
[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of IL1RAPL1 mRNA
CTD PMID:25119042 NCBI chr  X:55,439,388...57,004,865
Ensembl chr  X:55,439,578...56,765,893
JBrowse link
G Il2 interleukin 2 multiple interactions ISO PD 0325901 inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein]; PD 0325901 inhibits the reaction [IL2 protein results in increased expression of NCR3 protein]; PD 0325901 inhibits the reaction [IL2 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Inhba inhibin subunit beta A multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of INHBA mRNA CTD PMID:25119042 NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
JBrowse link
G Itga2 integrin subunit alpha 2 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ITGA2 mRNA
PD 0325901 results in decreased expression of ITGA2 mRNA
CTD PMID:25119042 NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
JBrowse link
G Itgbl1 integrin subunit beta like 1 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of ITGBL1 mRNA
PD 0325901 results in decreased expression of ITGBL1 mRNA
CTD PMID:25119042 NCBI chr15:110,114,148...110,378,970
Ensembl chr15:110,114,148...110,378,969
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression EXP PD 0325901 results in decreased expression of JUN mRNA CTD PMID:21976371 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kif24 kinesin family member 24 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of KIF24 mRNA
PD 0325901 results in decreased expression of KIF24 mRNA
CTD PMID:25119042 NCBI chr 5:57,778,730...57,845,642
Ensembl chr 5:57,780,389...57,845,509
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of KIT mRNA
PD 0325901 results in decreased expression of KIT mRNA
CTD PMID:25119042 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Klrk1 killer cell lectin like receptor K1 multiple interactions ISO PD 0325901 inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; PD 0325901 inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein] CTD PMID:27563819 NCBI chr 4:163,392,652...163,403,735
Ensembl chr 4:163,393,217...163,403,653
JBrowse link
G Kras KRAS proto-oncogene, GTPase multiple interactions ISO KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [PD 0325901 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [PD 0325901 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [PD 0325901 results in increased expression of BCL2L11 protein]]; KRAS protein affects the reaction [PD 0325901 inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [PD 0325901 promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [PD 0325901 results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [PD 0325901 results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [PD 0325901 results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [PD 0325901 results in increased expression of BCL2L11 protein]; KRAS protein affects the susceptibility to [[PD 0325901 co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; KRAS protein affects the susceptibility to [PD 0325901 co-treated with NVP-BKM120]
[PD 0325901 affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]
CTD PMID:24576621 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G LOC100362814 hypothetical protein LOC100362814 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of KIAA1549L mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of KIAA1549L mRNA
CTD PMID:25119042 NCBI chr 3:94,058,546...94,334,805
Ensembl chr 3:94,064,234...94,182,714
JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of LPL mRNA CTD PMID:25119042 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Lpxn leupaxin multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of LPXN mRNA
PD 0325901 results in decreased expression of LPXN mRNA
CTD PMID:25119042 NCBI chr 1:229,642,437...229,674,129
Ensembl chr 1:229,642,412...229,674,134
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO PD 0325901 inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32268164 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [PD 0325901 results in decreased phosphorylation of MAPK1 protein]; [MK 2206 co-treated with PD 0325901] results in decreased phosphorylation of MAPK1 protein; [PD 0325901 co-treated with silmitasertib] results in decreased phosphorylation of MAPK1 protein; dactolisib promotes the reaction [PD 0325901 results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [PD 0325901 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [PD 0325901 inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [PD 0325901 results in decreased phosphorylation of MAPK1 protein]; PD 0325901 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PD 0325901 inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; PD 0325901 inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]; PD 0325901 promotes the reaction [Axitinib results in decreased phosphorylation of MAPK1 protein]; PD 0325901 promotes the reaction [pazopanib results in decreased phosphorylation of MAPK1 protein]; PD 0325901 promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK1 protein]
PD 0325901 inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; PD 0325901 inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]
PD 0325901 inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]
CTD PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 PMID:25104499 PMID:25798061 PMID:27560553 PMID:27634878 PMID:29384525 PMID:32268164 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [PD 0325901 results in decreased phosphorylation of MAPK3 protein]; [MK 2206 co-treated with PD 0325901] results in decreased phosphorylation of MAPK3 protein; [PD 0325901 co-treated with silmitasertib] results in decreased phosphorylation of MAPK3 protein; dactolisib promotes the reaction [PD 0325901 results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [PD 0325901 results in decreased phosphorylation of MAPK3 protein]; PD 0325901 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PD 0325901 inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; PD 0325901 inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK3 protein]; PD 0325901 promotes the reaction [Axitinib results in decreased phosphorylation of MAPK3 protein]; PD 0325901 promotes the reaction [pazopanib results in decreased phosphorylation of MAPK3 protein]; PD 0325901 promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK3 protein]
PD 0325901 inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; PD 0325901 inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein]
PD 0325901 inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]
CTD PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 PMID:25104499 PMID:25798061 PMID:27560553 PMID:27634878 PMID:29384525 PMID:32268164 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
decreases expression
increases expression
ISO [PD 0325901 co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with PD 0325901 co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with PD 0325901] results in increased expression of MCL1 protein; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [PD 0325901 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [PD 0325901 promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [PD 0325901 results in decreased expression of MCL1 protein]; NVP-BKM120 promotes the reaction [PD 0325901 results in decreased expression of MCL1 protein]; PD 0325901 promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]
PD 0325901 results in increased expression of MCL1 protein
CTD PMID:24576621 PMID:27634878 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mgll monoglyceride lipase multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of MGLL mRNA
PD 0325901 results in decreased expression of MGLL mRNA
CTD PMID:25119042 NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [PD 0325901 affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]; PD 0325901 inhibits the reaction [camostat results in increased expression of MKI67 protein] CTD PMID:24576621 PMID:25104499 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mmd monocyte to macrophage differentiation-associated multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of MMD mRNA
PD 0325901 results in decreased expression of MMD mRNA
CTD PMID:25119042 NCBI chr10:77,687,964...77,783,737
Ensembl chr10:77,755,216...77,783,779
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of MMP1 mRNA
PD 0325901 results in decreased expression of MMP1 mRNA
CTD PMID:25119042 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp10 matrix metallopeptidase 10 multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of MMP10 mRNA CTD PMID:25119042 NCBI chr 8:5,734,348...5,742,243
Ensembl chr 8:5,734,348...5,742,243
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO PD 0325901 inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 0325901 inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:29384525 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression
ISO (+)-JQ1 compound promotes the reaction [PD 0325901 results in decreased expression of MYC protein]; PD 0325901 promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein] CTD PMID:26284497 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nav3 neuron navigator 3 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of NAV3 mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of NAV3 mRNA
CTD PMID:25119042 NCBI chr 7:52,164,805...52,508,145
Ensembl chr 7:52,165,233...52,404,774
JBrowse link
G Ncr3 natural cytotoxicity triggering receptor 3 multiple interactions ISO PD 0325901 inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; PD 0325901 inhibits the reaction [IL2 protein results in increased expression of NCR3 protein] CTD PMID:27563819 NCBI chr20:5,170,169...5,175,773
Ensembl chr20:5,170,215...5,175,773
JBrowse link
G Nf1 neurofibromin 1 multiple interactions ISO NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with PD 0325901]] CTD PMID:25119042 NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903
JBrowse link
G Nme5 NME/NM23 family member 5 multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of NME5 mRNA CTD PMID:25119042 NCBI chr18:27,357,460...27,374,641
Ensembl chr18:27,357,413...27,374,603
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 decreases expression ISO PD 0325901 results in decreased expression of NR0B2 mRNA CTD PMID:24819614 NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
JBrowse link
G Nrcam neuronal cell adhesion molecule decreases expression ISO PD 0325901 results in decreased expression of NRCAM mRNA CTD PMID:25119042 NCBI chr 6:64,297,843...64,867,408
Ensembl chr 6:64,297,888...64,864,996
JBrowse link
G Nrp1 neuropilin 1 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of NRP1 mRNA
PD 0325901 results in decreased expression of NRP1 mRNA
CTD PMID:25119042 NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
JBrowse link
G Ntm neurotrimin multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of NTM mRNA
PD 0325901 results in decreased expression of NTM mRNA
CTD PMID:25119042 NCBI chr 8:30,039,332...31,041,755
Ensembl chr 8:30,039,408...30,222,036
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [PD 0325901 co-treated with MK 2206] results in increased cleavage of PARP1 protein; [PD 0325901 co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein; KRAS protein affects the susceptibility to [[PD 0325901 co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; PD 0325901 promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [[PD 0325901 co-treated with MK 2206] results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [PD 0325901 results in increased cleavage of PARP1 protein] CTD PMID:24576621 PMID:27634878 PMID:32268164 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO PD 0325901 inhibits the reaction [camostat results in increased expression of PCNA protein] CTD PMID:25104499 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pdcd1lg2 programmed cell death 1 ligand 2 multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of PDCD1LG2 mRNA CTD PMID:25119042 NCBI chr 1:247,562,202...247,629,279
Ensembl chr 1:247,562,202...247,627,193
JBrowse link
G Peg3 paternally expressed 3 decreases expression ISO PD 0325901 results in decreased expression of PEG3 mRNA CTD PMID:25119042 NCBI chr 1:70,210,810...70,237,450
Ensembl chr 1:70,222,964...70,237,443
JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of PLAU mRNA
PD 0325901 results in decreased expression of PLAU mRNA
CTD PMID:25119042 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of PLAUR mRNA
PD 0325901 results in decreased expression of PLAUR mRNA
CTD PMID:25119042 NCBI chr 1:81,328,171...81,344,954
Ensembl chr 1:81,328,183...81,344,708
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO PD 0325901 inhibits the reaction [Protein Kinase Inhibitors results in increased phosphorylation of and results in decreased activity of PPARG protein] CTD PMID:26670611 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Prdm1 PR/SET domain 1 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of PRDM1 mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of PRDM1 mRNA
CTD PMID:25119042 NCBI chr20:49,464,921...49,556,623
Ensembl chr20:49,464,919...49,556,518
JBrowse link
G Prrx1 paired related homeobox 1 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of PRRX1 mRNA
PD 0325901 results in decreased expression of PRRX1 mRNA
CTD PMID:25119042 NCBI chr13:81,147,038...81,215,559
Ensembl chr13:81,147,348...81,214,546
JBrowse link
G Ptx3 pentraxin 3 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of PTX3 mRNA
PD 0325901 results in decreased expression of PTX3 mRNA
CTD PMID:25119042 NCBI chr 2:158,097,843...158,103,653
Ensembl chr 2:158,097,843...158,103,653
JBrowse link
G Rac1 Rac family small GTPase 1 affects response to substance ISO RAC1 protein alternative form affects the susceptibility to PD 0325901 CTD PMID:23033341 NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
JBrowse link
G Reln reelin decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of RELN mRNA
[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of RELN mRNA
CTD PMID:25119042 NCBI chr 4:9,347,533...9,774,257
Ensembl chr 4:9,347,528...9,773,670
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
ISO 2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one promotes the reaction [PD 0325901 results in decreased phosphorylation of RPS6 protein]; PD 0325901 promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein]; PD 0325901 promotes the reaction [dactolisib results in decreased phosphorylation of RPS6 protein]; PD 0325901 promotes the reaction [NVP-BKM120 results in decreased phosphorylation of RPS6 protein] CTD PMID:22415236 PMID:24011934 PMID:24576621 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Scg5 secretogranin V multiple interactions ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of SCG5 mRNA CTD PMID:25119042 NCBI chr 3:105,235,065...105,279,475
Ensembl chr 3:105,235,050...105,279,462
JBrowse link
G Sema3a semaphorin 3A multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SEMA3A mRNA
PD 0325901 results in decreased expression of SEMA3A mRNA
CTD PMID:25119042 NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035
JBrowse link
G Siglec15 sialic acid binding Ig-like lectin 15 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of SIGLEC15 mRNA
PD 0325901 results in decreased expression of SIGLEC15 mRNA
CTD PMID:25119042 NCBI chr18:74,403,384...74,417,333
Ensembl chr18:74,403,384...74,417,333
JBrowse link
G Slc6a15 solute carrier family 6 member 15 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SLC6A15 mRNA
PD 0325901 results in decreased expression of SLC6A15 mRNA
CTD PMID:25119042 NCBI chr 7:45,328,207...45,381,920
Ensembl chr 7:45,328,105...45,382,229
JBrowse link
G Slit2 slit guidance ligand 2 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SLIT2 mRNA
PD 0325901 results in decreased expression of SLIT2 mRNA
CTD PMID:25119042 NCBI chr14:66,831,848...67,171,491
Ensembl chr14:66,831,848...67,170,361
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression ISO PD 0325901 results in decreased expression of SOX9 mRNA CTD PMID:25119042 NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SPP1 mRNA CTD PMID:25119042 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Spry2 sprouty RTK signaling antagonist 2 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SPRY2 mRNA
PD 0325901 results in decreased expression of SPRY2 mRNA
CTD PMID:25119042 NCBI chr15:90,172,769...90,177,823
Ensembl chr15:90,172,975...90,175,802
JBrowse link
G St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ST3GAL6 mRNA
PD 0325901 results in decreased expression of ST3GAL6 mRNA
CTD PMID:25119042 NCBI chr11:44,176,518...44,237,119
Ensembl chr11:44,192,940...44,237,100
JBrowse link
G Stc1 stanniocalcin 1 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of STC1 mRNA
[(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of STC1 mRNA
CTD PMID:25119042 NCBI chr15:50,891,137...50,901,791
Ensembl chr15:50,891,127...50,903,162
JBrowse link
G Stx1a syntaxin 1A multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of STX1A mRNA
PD 0325901 results in decreased expression of STX1A mRNA
CTD PMID:25119042 NCBI chr12:24,682,050...24,710,002
Ensembl chr12:24,682,041...24,710,019
JBrowse link
G Suz12 SUZ12 polycomb repressive complex 2 subunit multiple interactions ISO NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with PD 0325901]]; SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with PD 0325901] CTD PMID:25119042 NCBI chr10:67,325,101...67,371,588
Ensembl chr10:67,325,347...67,369,668
JBrowse link
G Syngap1 synaptic Ras GTPase activating protein 1 affects response to substance ISO SYNGAP1 protein affects the susceptibility to PD 0325901 CTD PMID:29940508 NCBI chr20:5,535,434...5,564,657
Ensembl chr20:5,535,432...5,564,437
JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of TBX3 mRNA
PD 0325901 results in decreased expression of TBX3 mRNA
CTD PMID:25119042 NCBI chr12:42,479,518...42,494,588
Ensembl chr12:42,480,560...42,492,526
JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of TFPI mRNA
PD 0325901 results in decreased expression of TFPI mRNA
CTD PMID:25119042 NCBI chr 3:71,852,738...71,902,127
Ensembl chr 3:71,852,744...71,893,618
JBrowse link
G Tgm2 transglutaminase 2 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of TGM2 mRNA
PD 0325901 results in decreased expression of TGM2 mRNA
CTD PMID:25119042 NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
JBrowse link
G Tlr4 toll-like receptor 4 decreases expression
multiple interactions
ISO PD 0325901 results in decreased expression of TLR4 mRNA
[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of TLR4 mRNA
CTD PMID:25119042 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tmem156 transmembrane protein 156 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of TMEM156 mRNA
PD 0325901 results in decreased expression of TMEM156 mRNA
CTD PMID:25119042 NCBI chr14:44,888,902...44,918,377
Ensembl chr14:44,889,287...44,918,373
JBrowse link
G Tnfsf15 TNF superfamily member 15 multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of TNFSF15 mRNA
PD 0325901 results in decreased expression of TNFSF15 mRNA
CTD PMID:25119042 NCBI chr 5:79,553,935...79,569,974
Ensembl chr 5:79,553,742...79,570,073
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [PD 0325901 co-treated with MK 2206] results in increased expression of and results in increased phosphorylation of TRP53 protein CTD PMID:28691888 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Trib2 tribbles pseudokinase 2 multiple interactions
decreases expression
ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of TRIB2 mRNA
PD 0325901 results in decreased expression of TRIB2 mRNA
CTD PMID:25119042 NCBI chr 6:41,016,722...41,040,972
Ensembl chr 6:41,016,730...41,039,437
JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO PD 0325901 inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]] CTD PMID:26670611 NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
JBrowse link
G Ugt8 UDP glycosyltransferase 8 multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of UGT8 mRNA CTD PMID:25119042 NCBI chr 2:229,644,373...229,718,678
Ensembl chr 2:229,644,382...229,718,659
JBrowse link
G Vegfc vascular endothelial growth factor C multiple interactions
decreases expression
ISO [(+)-JQ1 compound co-treated with PD 0325901] results in decreased expression of VEGFC mRNA
PD 0325901 results in decreased expression of VEGFC mRNA
CTD PMID:25119042 NCBI chr16:40,440,371...40,555,178
Ensembl chr16:40,440,207...40,555,576
JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 multiple interactions ISO [PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of ZEB1 mRNA CTD PMID:25119042 NCBI chr17:54,656,627...54,714,920
Ensembl chr17:54,658,463...54,714,914
JBrowse link
trovafloxacin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha decreases expression EXP trovafloxacin results in decreased expression of ACACA mRNA CTD PMID:24136188 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Acsf2 acyl-CoA synthetase family member 2 decreases expression EXP trovafloxacin results in decreased expression of ACSF2 mRNA CTD PMID:24136188 NCBI chr10:82,284,719...82,326,771
Ensembl chr10:82,284,720...82,326,771
JBrowse link
G Actb actin, beta decreases expression EXP trovafloxacin results in decreased expression of ACTB mRNA CTD PMID:24136188 NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
JBrowse link
G Actg1 actin, gamma 1 decreases expression EXP trovafloxacin results in decreased expression of ACTG1 mRNA CTD PMID:24136188 NCBI chr10:109,518,429...109,521,288
Ensembl chr 3:75,643,054...75,644,954
Ensembl chr10:75,643,054...75,644,954
JBrowse link
G Acy1 aminoacylase 1 decreases expression EXP trovafloxacin results in decreased expression of ACY1 mRNA CTD PMID:24136188 NCBI chr 8:115,134,792...115,140,171
Ensembl chr 8:115,134,765...115,140,080
JBrowse link
G Adap2 ArfGAP with dual PH domains 2 increases expression EXP trovafloxacin results in increased expression of ADAP2 mRNA CTD PMID:24136188 NCBI chr10:67,494,851...67,527,582
Ensembl chr10:67,494,984...67,526,426
JBrowse link
G Adipor2 adiponectin receptor 2 decreases expression EXP trovafloxacin results in decreased expression of ADIPOR2 mRNA CTD PMID:24136188 NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ADRB2 mRNA CTD PMID:18930950 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 decreases expression EXP trovafloxacin results in decreased expression of AKR7A3 mRNA CTD PMID:24136188 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 decreases expression EXP trovafloxacin results in decreased expression of ALDH1A1 mRNA CTD PMID:24136188 NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 decreases expression EXP trovafloxacin results in decreased expression of ALDH1B1 mRNA CTD PMID:24136188 NCBI chr 5:61,382,351...61,387,359
Ensembl chr 5:61,382,351...61,387,358
JBrowse link
G Amd1 adenosylmethionine decarboxylase 1 decreases expression EXP trovafloxacin results in decreased expression of AMD1 mRNA CTD PMID:24136188 NCBI chr20:45,384,000...45,399,694
Ensembl chr20:45,384,000...45,399,694
JBrowse link
G Ammecr1l AMMECR1 like increases expression EXP trovafloxacin results in increased expression of AMMECR1L mRNA CTD PMID:24136188 NCBI chr18:24,539,530...24,563,576
Ensembl chr18:24,540,659...24,563,576
JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ANGPTL4 mRNA CTD PMID:18930950 NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
JBrowse link
G Ankhd1 ankyrin repeat and KH domain containing 1 increases expression EXP trovafloxacin results in increased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:24136188 NCBI chr18:29,386,906...29,485,611
Ensembl chr18:29,386,809...29,492,718
JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression EXP trovafloxacin results in decreased expression of AP1S1 mRNA CTD PMID:24136188 NCBI chr12:22,665,128...22,676,079
Ensembl chr12:22,665,112...22,676,075
JBrowse link
G Apex1 apurinic/apyrimidinic endodeoxyribonuclease 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of APEX1 mRNA CTD PMID:18930950 NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
JBrowse link
G Apoa5 apolipoprotein A5 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of APOA5 mRNA CTD PMID:18930950 NCBI chr 8:50,559,079...50,561,720
Ensembl chr 8:50,559,126...50,561,736
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 decreases expression EXP trovafloxacin results in decreased expression of ARHGAP24 mRNA CTD PMID:24136188 NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512
JBrowse link
G Arid5b AT-rich interaction domain 5B multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ARID5B mRNA CTD PMID:18930950 NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715
JBrowse link
G Armt1 acidic residue methyltransferase 1 decreases expression EXP trovafloxacin results in decreased expression of ARMT1 mRNA CTD PMID:24136188 NCBI chr 1:40,982,761...41,006,371
Ensembl chr 1:40,982,862...41,006,371
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
ISO pyrazolanthrone inhibits the reaction [trovafloxacin results in increased phosphorylation of ATF2 protein] CTD PMID:24525298 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
JBrowse link
G Atp6v0e2 ATPase, H+ transporting V0 subunit e2 decreases expression EXP trovafloxacin results in decreased expression of ATP6V0E2 mRNA CTD PMID:24136188 NCBI chr 4:78,168,117...78,171,265
Ensembl chr 4:78,168,117...78,171,265
JBrowse link
G Atr ATR serine/threonine kinase multiple interactions ISO 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of ATR protein]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased phosphorylation of ATR protein]; [trovafloxacin co-treated with TNF protein] results in increased phosphorylation of and results in increased activity of ATR protein; trovafloxacin results in increased phosphorylation of and results in increased activity of ATR protein; U 0126 inhibits the reaction [trovafloxacin results in increased activity of ATR protein] CTD PMID:25748550 NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
JBrowse link
G Atrn attractin increases expression EXP trovafloxacin results in increased expression of ATRN mRNA CTD PMID:24136188 NCBI chr 3:123,434,409...123,567,922
Ensembl chr 3:123,434,409...123,567,918
JBrowse link
G B2m beta-2 microglobulin multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of B2M mRNA CTD PMID:18930950 NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BHLHE40 mRNA CTD PMID:18930950 NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions
decreases expression
ISO trovafloxacin inhibits the reaction [TNF protein results in increased expression of BIRC2 mRNA]
trovafloxacin results in decreased expression of BIRC2 protein
[trovafloxacin co-treated with TNF protein] results in decreased expression of BIRC2 mRNA
trovafloxacin results in decreased expression of BIRC2 mRNA
CTD PMID:32035082 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions
decreases expression
ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BIRC3 mRNA
[trovafloxacin co-treated with TNF protein] results in increased expression of BIRC3 mRNA
trovafloxacin results in decreased expression of BIRC3 mRNA
CTD PMID:18930950 PMID:32035082 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Bpnt1 3'(2'), 5'-bisphosphate nucleotidase 1 decreases expression EXP trovafloxacin results in decreased expression of BPNT1 mRNA CTD PMID:24136188 NCBI chr13:103,268,045...103,292,848
Ensembl chr13:103,268,068...103,292,854
JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression EXP trovafloxacin results in decreased expression of BST2 mRNA CTD PMID:24136188 NCBI chr16:19,938,781...19,942,353
Ensembl chr16:19,938,784...19,942,353
JBrowse link
G Caprin1 cell cycle associated protein 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CAPRIN1 mRNA CTD PMID:18930950 NCBI chr 3:93,701,830...93,789,580
Ensembl chr 3:93,702,487...93,789,617
JBrowse link
G Casd1 CAS1 domain containing 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASD1 mRNA CTD PMID:18930950 NCBI chr 4:29,638,280...29,693,151
Ensembl chr 4:29,639,154...29,691,928
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
ISO [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [TNF protein co-treated with trovafloxacin] results in increased activity of CASP3 protein; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL1B protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL6 protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with TNF protein] results in increased activity of CASP3 protein; U 0126 inhibits the reaction [[TNF protein co-treated with trovafloxacin] results in increased activity of CASP3 protein]
[TNF protein co-treated with trovafloxacin] results in increased cleavage of CASP3 protein
CTD PMID:19638433 PMID:24097668 PMID:25748550 PMID:30876886 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp6 caspase 6 increases expression EXP trovafloxacin results in increased expression of CASP6 mRNA CTD PMID:24136188 NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967
Ensembl chr 2:235,341,365...235,353,967
JBrowse link
G Casp7 caspase 7 decreases expression EXP trovafloxacin results in decreased expression of CASP7 mRNA CTD PMID:24136188 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [trovafloxacin co-treated with TNF protein] results in increased activity of CASP8 protein CTD PMID:24097668 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [trovafloxacin co-treated with TNF protein] results in increased activity of CASP9 protein CTD PMID:24097668 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccdc6 coiled-coil domain containing 6 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCDC6 mRNA CTD PMID:18930950 NCBI chr20:19,729,005...19,825,219
Ensembl chr20:19,732,894...19,825,150
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO trovafloxacin promotes the reaction [TNF protein results in increased expression of CCL2 protein] CTD PMID:19638433 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccnb2 cyclin B2 decreases expression EXP trovafloxacin results in decreased expression of CCNB2 mRNA CTD PMID:24136188 NCBI chr 8:76,847,972...76,861,165 JBrowse link
G Ccnd1 cyclin D1 decreases expression EXP trovafloxacin results in decreased expression of CCND1 mRNA CTD PMID:24136188 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cd36 CD36 molecule decreases expression EXP trovafloxacin results in decreased expression of CD36 mRNA CTD PMID:24136188 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cd8b CD8b molecule multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CD8B mRNA CTD PMID:18930950 NCBI chr 4:99,185,960...99,201,887
Ensembl chr 4:99,185,885...99,202,023
JBrowse link
G Cdc20 cell division cycle 20 decreases expression EXP trovafloxacin results in decreased expression of CDC20 mRNA CTD PMID:24136188 NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
JBrowse link
G Cdc42ep4 CDC42 effector protein 4 increases expression EXP trovafloxacin results in increased expression of CDC42EP4 mRNA CTD PMID:24136188 NCBI chr10:102,244,680...102,269,272
Ensembl chr10:102,244,681...102,269,272
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression EXP trovafloxacin results in decreased expression of CDK1 mRNA CTD PMID:24136188 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk16 cyclin-dependent kinase 16 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CDK16 mRNA CTD PMID:18930950 NCBI chr  X:1,707,285...1,718,821
Ensembl chr  X:1,707,289...1,718,637
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CDKN1A mRNA
trovafloxacin results in increased expression of CDKN1A mRNA
CTD PMID:18930950 PMID:25748550 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn3 cyclin-dependent kinase inhibitor 3 decreases expression EXP trovafloxacin results in decreased expression of CDKN3 mRNA CTD PMID:24136188 NCBI chr15:23,553,171...23,564,538
Ensembl chr15:23,553,128...23,564,535
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CEBPA mRNA CTD PMID:18930950 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CHFR mRNA CTD PMID:18930950 NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
JBrowse link
G Chka choline kinase alpha multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CHKA mRNA CTD PMID:18930950 NCBI chr 1:219,076,618...219,126,221
Ensembl chr 1:219,077,771...219,126,220
JBrowse link
G Cks2 CDC28 protein kinase regulatory subunit 2 decreases expression EXP trovafloxacin results in decreased expression of CKS2 mRNA CTD PMID:24136188 NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423
JBrowse link
G Cldn14 claudin 14 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CLDN14 mRNA CTD PMID:18930950 NCBI chr11:34,132,581...34,142,813
Ensembl chr11:34,132,581...34,142,753
JBrowse link
G Clint1 clathrin interactor 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CLINT1 mRNA CTD PMID:18930950 NCBI chr10:30,833,914...31,007,813
Ensembl chr10:30,833,914...31,007,820
JBrowse link
G Comt catechol-O-methyltransferase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of COMT mRNA CTD PMID:18930950 NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
JBrowse link
G Copg1 COPI coat complex subunit gamma 1 decreases expression EXP trovafloxacin results in decreased expression of COPG1 mRNA CTD PMID:24136188 NCBI chr 4:119,815,041...119,840,997
Ensembl chr 4:119,815,139...119,864,114
JBrowse link
G Cpox coproporphyrinogen oxidase decreases expression EXP trovafloxacin results in decreased expression of CPOX mRNA CTD PMID:24136188 NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression EXP trovafloxacin results in increased expression of CPT1A mRNA CTD PMID:24136188 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Crk CRK proto-oncogene, adaptor protein multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CRK mRNA CTD PMID:18930950 NCBI chr10:63,829,731...63,855,999
Ensembl chr10:63,829,807...63,852,780
JBrowse link
G Cs citrate synthase decreases expression EXP trovafloxacin results in decreased expression of CS mRNA CTD PMID:24136188 NCBI chr 7:2,752,680...2,778,963
Ensembl chr 7:2,752,680...2,778,963
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CXCL2 mRNA; trovafloxacin promotes the reaction [TNF protein results in increased expression of CXCL2 protein] CTD PMID:18930950 PMID:19638433 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CXCL3 mRNA; trovafloxacin promotes the reaction [TNF protein results in increased expression of CXCL1 protein] CTD PMID:18930950 PMID:19638433 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases activity ISO trovafloxacin results in decreased activity of CYP19A1 protein CTD PMID:26141389 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp2b12 cytochrome P450, family 2, subfamily b, polypeptide 12 decreases expression EXP trovafloxacin results in decreased expression of CYP2B12 mRNA CTD PMID:24136188 NCBI chr 1:83,511,167...83,522,965
Ensembl chr 1:83,511,167...83,584,589
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CYP7A1 mRNA CTD PMID:18930950 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 increases expression EXP trovafloxacin results in increased expression of CYP8B1 mRNA CTD PMID:24136188 NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
JBrowse link
G Dapk1 death associated protein kinase 1 decreases expression EXP trovafloxacin results in decreased expression of DAPK1 mRNA CTD PMID:24136188 NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 decreases expression ISO trovafloxacin results in decreased expression of DDIT3 mRNA CTD PMID:24136188 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ddx1 DEAD-box helicase 1 decreases expression EXP trovafloxacin results in decreased expression of DDX1 mRNA CTD PMID:24136188 NCBI chr 6:38,422,892...38,453,762
Ensembl chr 6:38,422,888...38,453,797
JBrowse link
G Ddx17 DEAD-box helicase 17 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of DDX17 mRNA CTD PMID:18930950 NCBI chr 7:120,761,843...120,765,012
Ensembl chr 7:120,761,826...120,780,641
JBrowse link
G Derl2 derlin 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of DERL2 mRNA CTD PMID:18930950 NCBI chr10:57,641,682...57,653,554
Ensembl chr10:57,644,207...57,653,359
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 decreases expression EXP trovafloxacin results in decreased expression of DGAT2 mRNA CTD PMID:24136188 NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
JBrowse link
G Dlst dihydrolipoamide S-succinyltransferase decreases expression EXP trovafloxacin results in decreased expression of DLST mRNA CTD PMID:24136188 NCBI chr 6:108,936,534...108,961,322
Ensembl chr 6:108,936,664...108,959,803
JBrowse link
G Dnajb2 DnaJ heat shock protein family (Hsp40) member B2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of DNAJB2 mRNA CTD PMID:18930950 NCBI chr 9:82,436,453...82,444,669
Ensembl chr 9:82,436,458...82,444,668
JBrowse link
G Dnph1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 decreases expression EXP trovafloxacin results in decreased expression of DNPH1 mRNA CTD PMID:24136188 NCBI chr 9:16,845,764...16,848,514
Ensembl chr 9:16,845,525...16,848,503
JBrowse link
G Dtymk deoxythymidylate kinase decreases expression EXP trovafloxacin results in decreased expression of DTYMK mRNA CTD PMID:24136188 NCBI chr 9:100,921,565...100,930,399
Ensembl chr 9:100,921,565...100,930,399
JBrowse link
G Dusp16 dual specificity phosphatase 16 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of DUSP16 mRNA CTD PMID:18930950 NCBI chr 4:168,470,141...168,551,346
Ensembl chr 4:168,472,412...168,517,177
JBrowse link
G Dusp8 dual specificity phosphatase 8 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of DUSP8 mRNA CTD PMID:18930950 NCBI chr 1:215,030,429...215,043,111
Ensembl chr 1:215,030,429...215,033,460
JBrowse link
G Dut deoxyuridine triphosphatase decreases expression EXP trovafloxacin results in decreased expression of DUT mRNA CTD PMID:24136188 NCBI chr 3:117,514,399...117,525,450
Ensembl chr 3:117,514,444...117,525,446
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EGFR mRNA CTD PMID:18930950 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha decreases expression EXP trovafloxacin results in decreased expression of EIF2S1 mRNA CTD PMID:24136188 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Eif2s2 eukaryotic translation initiation factor 2 subunit beta multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EIF2S2 mRNA CTD PMID:18930950 NCBI chr 3:150,391,455...150,412,179
Ensembl chr 3:150,391,460...150,412,179
JBrowse link
G Eif3a eukaryotic translation initiation factor 3, subunit A multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of EIF3A mRNA CTD PMID:18930950 NCBI chr 1:282,139,809...282,170,017
Ensembl chr 1:282,139,823...282,170,017
JBrowse link
G Eif3c eukaryotic translation initiation factor 3, subunit C decreases expression EXP trovafloxacin results in decreased expression of EIF3C mRNA CTD PMID:24136188 NCBI chr 1:197,964,406...197,982,917
Ensembl chr 1:197,964,407...197,982,601
JBrowse link
G Eif3l eukaryotic translation initiation factor 3, subunit L decreases expression EXP trovafloxacin results in decreased expression of EIF3L mRNA CTD PMID:24136188 NCBI chr 7:120,320,547...120,331,596
Ensembl chr 7:120,320,547...120,331,595
JBrowse link
G Eif4a2 eukaryotic translation initiation factor 4A2 increases expression EXP trovafloxacin results in increased expression of EIF4A2 mRNA CTD PMID:24136188 NCBI chr11:81,373,047...81,379,680
Ensembl chr11:81,373,048...81,379,871
JBrowse link
G Eif6 eukaryotic translation initiation factor 6 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EIF6 mRNA CTD PMID:18930950 NCBI chr 3:151,356,867...151,363,201
Ensembl chr 3:151,356,868...151,363,115
JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 decreases expression EXP trovafloxacin results in decreased expression of ELOVL6 mRNA CTD PMID:24136188 NCBI chr 2:234,187,490...234,296,124
Ensembl chr 2:234,189,105...234,296,145
Ensembl chr 2:234,189,105...234,296,145
JBrowse link
G Emc1 ER membrane protein complex subunit 1 decreases expression EXP trovafloxacin results in decreased expression of EMC1 mRNA CTD PMID:24136188 NCBI chr 5:157,820,908...157,846,226
Ensembl chr 5:157,820,908...157,846,226
JBrowse link
G Ephx1 epoxide hydrolase 1 decreases expression EXP trovafloxacin results in decreased expression of EPHX1 mRNA CTD PMID:24136188 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Ergic1 endoplasmic reticulum-golgi intermediate compartment 1 decreases expression EXP trovafloxacin results in decreased expression of ERGIC1 mRNA CTD PMID:24136188 NCBI chr10:16,821,393...16,912,050
Ensembl chr10:16,821,880...16,910,641
JBrowse link
G Erp29 endoplasmic reticulum protein 29 decreases expression EXP trovafloxacin results in decreased expression of ERP29 mRNA CTD PMID:24136188 NCBI chr12:40,619,377...40,625,884
Ensembl chr12:40,619,377...40,625,883
JBrowse link
G Errfi1 ERBB receptor feedback inhibitor 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ERRFI1 mRNA CTD PMID:18930950 NCBI chr 5:167,951,564...167,966,011
Ensembl chr 5:167,952,728...167,966,009
JBrowse link
G Ets2 ETS proto-oncogene 2, transcription factor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ETS2 mRNA CTD PMID:18930950 NCBI chr11:36,075,709...36,092,495
Ensembl chr11:36,075,709...36,092,495
JBrowse link
G F2 coagulation factor II multiple interactions ISO [Lipopolysaccharides co-treated with trovafloxacin] results in increased activity of F2 protein CTD PMID:19367693 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link
G Fam98a family with sequence similarity 98, member A decreases expression EXP trovafloxacin results in decreased expression of FAM98A mRNA CTD PMID:24136188 NCBI chr 6:21,051,327...21,065,986
Ensembl chr 6:21,051,327...21,065,986
JBrowse link
G Fasn fatty acid synthase multiple interactions
decreases expression
ISO
EXP
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of FASN mRNA
trovafloxacin results in decreased expression of FASN mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fbxo9 f-box protein 9 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of FBXO9 mRNA CTD PMID:18930950 NCBI chr 8:85,388,331...85,413,896
Ensembl chr 8:85,388,333...85,413,484
JBrowse link
G Fga fibrinogen alpha chain multiple interactions ISO [Lipopolysaccharides co-treated with trovafloxacin] results in increased expression of FGA protein CTD PMID:19367693 NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
JBrowse link
G Fkbp4 FKBP prolyl isomerase 4 decreases expression EXP trovafloxacin results in decreased expression of FKBP4 mRNA CTD PMID:24136188 NCBI chr 4:161,748,993...161,757,447
Ensembl chr 4:161,748,993...161,757,447
JBrowse link
G Fmo3 flavin containing dimethylaniline monoxygenase 3 increases expression EXP trovafloxacin results in increased expression of FMO3 mRNA CTD PMID:24136188 NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of FOS mRNA CTD PMID:18930950 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Fzd7 frizzled class receptor 7 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of FZD7 mRNA CTD PMID:18930950 NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of G6PC mRNA CTD PMID:18930950 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases expression EXP trovafloxacin results in decreased expression of G6PD mRNA CTD PMID:24136188 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases expression EXP trovafloxacin results in decreased expression of GADD45G mRNA CTD PMID:24136188 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression EXP trovafloxacin results in decreased expression of GAPDH mRNA CTD PMID:24136188 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Gcgr glucagon receptor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GCGR mRNA CTD PMID:18930950 NCBI chr10:109,707,863...109,716,253
Ensembl chr10:109,707,962...109,716,128
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit decreases expression
multiple interactions
EXP
ISO
trovafloxacin results in decreased expression of GCLC mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GCLC mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gfm1 G elongation factor, mitochondrial 1 decreases expression EXP trovafloxacin results in decreased expression of GFM1 mRNA CTD PMID:24136188 NCBI chr 2:164,601,575...164,646,478
Ensembl chr 2:164,601,586...164,646,439
JBrowse link
G Ggcx gamma-glutamyl carboxylase decreases expression EXP trovafloxacin results in decreased expression of GGCX mRNA CTD PMID:24136188 NCBI chr 4:100,277,345...100,293,097
Ensembl chr 4:100,277,391...100,293,250
JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GJA1 mRNA CTD PMID:18930950 NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
JBrowse link
G Glrx3 glutaredoxin 3 decreases expression EXP trovafloxacin results in decreased expression of GLRX3 mRNA CTD PMID:24136188 NCBI chr 1:209,768,696...209,799,912
Ensembl chr 1:209,768,696...209,799,903
JBrowse link
G Glyat glycine-N-acyltransferase increases expression EXP trovafloxacin results in increased expression of GLYAT mRNA CTD PMID:24136188 NCBI chr 1:229,060,125...229,081,113
Ensembl chr 1:229,063,714...229,080,410
JBrowse link
G Gnl3 G protein nucleolar 3 increases expression EXP trovafloxacin results in increased expression of GNL3 mRNA CTD PMID:24136188 NCBI chr16:7,097,580...7,103,518
Ensembl chr16:7,097,507...7,103,604
JBrowse link
G Gnpnat1 glucosamine-phosphate N-acetyltransferase 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GNPNAT1 mRNA CTD PMID:18930950 NCBI chr15:19,721,292...19,734,032
Ensembl chr15:19,721,293...19,733,967
JBrowse link
G Golga2 golgin A2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GOLGA2 mRNA CTD PMID:18930950 NCBI chr 3:11,317,328...11,337,569
Ensembl chr 3:11,317,183...11,336,458
JBrowse link
G Golga4 golgin A4 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GOLGA4 mRNA CTD PMID:18930950 NCBI chr 8:127,171,221...127,248,938
Ensembl chr 8:127,171,537...127,248,538
JBrowse link
G Gpam glycerol-3-phosphate acyltransferase, mitochondrial decreases expression EXP trovafloxacin results in decreased expression of GPAM mRNA CTD PMID:24136188 NCBI chr 1:275,843,823...275,906,880
Ensembl chr 1:275,846,819...275,906,686
JBrowse link
G Gpld1 glycosylphosphatidylinositol specific phospholipase D1 increases expression EXP trovafloxacin results in increased expression of GPLD1 mRNA CTD PMID:24136188 NCBI chr17:42,085,027...42,131,344
Ensembl chr17:42,085,028...42,127,678
JBrowse link
G Gsr glutathione-disulfide reductase decreases expression EXP trovafloxacin results in decreased expression of GSR mRNA CTD PMID:24136188 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Gss glutathione synthetase decreases expression EXP trovafloxacin results in decreased expression of GSS mRNA CTD PMID:24136188 NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
JBrowse link
G Gsta3 glutathione S-transferase alpha 3 decreases expression EXP trovafloxacin results in decreased expression of GSTA3 mRNA CTD PMID:24136188 NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases phosphorylation
increases expression
ISO [TNF protein co-treated with trovafloxacin] results in increased expression of H2AX protein modified form; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[TNF protein co-treated with trovafloxacin] results in increased expression of H2AX protein modified form]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [trovafloxacin results in increased expression of H2AX protein modified form]; TNF protein promotes the reaction [trovafloxacin results in increased expression of H2AX protein modified form]
trovafloxacin results in increased phosphorylation of H2AX protein
CTD PMID:24817034 PMID:25748550 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Hacd3 3-hydroxyacyl-CoA dehydratase 3 decreases expression EXP trovafloxacin results in decreased expression of HACD3 mRNA CTD PMID:24136188 NCBI chr 8:70,471,572...70,509,874
Ensembl chr 8:70,471,572...70,509,874
JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 increases expression EXP trovafloxacin results in increased expression of HACL1 mRNA CTD PMID:24136188 NCBI chr16:7,720,047...7,758,119
Ensembl chr16:7,714,465...7,758,189
JBrowse link
G Hao2 hydroxyacid oxidase 2 increases expression EXP trovafloxacin results in increased expression of HAO2 mRNA CTD PMID:24136188 NCBI chr 2:200,785,492...200,808,868
Ensembl chr 2:200,778,122...200,808,857
JBrowse link
G Hmgn3 high mobility group nucleosomal binding domain 3 decreases expression EXP trovafloxacin results in decreased expression of HMGN3 mRNA CTD PMID:24136188 NCBI chr 8:90,628,203...90,665,055
Ensembl chr 8:90,628,209...90,664,554
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HMOX1 mRNA CTD PMID:18930950 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hnrnpf heterogeneous nuclear ribonucleoprotein F multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of HNRNPF mRNA CTD PMID:18930950 NCBI chr 4:149,957,143...149,978,896
Ensembl chr 4:149,957,206...149,978,895
JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 decreases expression EXP trovafloxacin results in decreased expression of HSPH1 mRNA CTD PMID:24136188 NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 decreases expression EXP trovafloxacin results in decreased expression of HTATIP2 mRNA CTD PMID:24136188 NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ICAM1 mRNA; trovafloxacin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
[trovafloxacin co-treated with TNF protein] results in increased expression of ICAM1 mRNA
trovafloxacin results in decreased expression of ICAM1 mRNA
CTD PMID:18930950 PMID:32035082 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Id2 inhibitor of DNA binding 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of ID2 mRNA CTD PMID:18930950 NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
JBrowse link
G Ide insulin degrading enzyme decreases expression EXP trovafloxacin results in decreased expression of IDE mRNA CTD PMID:24136188 NCBI chr 1:255,914,465...256,014,168
Ensembl chr 1:255,914,447...256,013,495
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 decreases expression EXP trovafloxacin results in decreased expression of IDH2 mRNA CTD PMID:24136188 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Ifng interferon gamma multiple interactions ISO
EXP
IFNG protein promotes the reaction [[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF protein]; IFNG protein results in increased susceptibility to [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5]; trovafloxacin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNG protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IFNG protein]
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin
CTD PMID:18930950 PMID:19362101 PMID:19638433 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Ifrd1 interferon-related developmental regulator 1 increases expression
multiple interactions
EXP
ISO
trovafloxacin results in increased expression of IFRD1 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IFRD1 mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr 6:60,132,025...60,151,354
Ensembl chr 6:60,132,024...60,151,420
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IGFBP1 mRNA CTD PMID:18930950 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Il17ra interleukin 17 receptor A multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL17RA mRNA CTD PMID:18930950 NCBI chr 4:152,995,865...153,018,394
Ensembl chr 4:152,995,865...153,018,394
JBrowse link
G Il18 interleukin 18 multiple interactions ISO IL18 protein results in increased susceptibility to [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5]; trovafloxacin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL18 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IL18 protein] CTD PMID:18930950 PMID:19638433 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO
EXP
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin CTD PMID:19362101 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL1B protein] affects the localization of SELE protein; [trovafloxacin co-treated with IL1B protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL1B protein] results in increased expression of SELE mRNA; trovafloxacin promotes the reaction [IL1B protein results in increased secretion of SELE protein]
trovafloxacin promotes the reaction [TNF protein results in increased expression of IL1B protein]
CTD PMID:10822086 PMID:19638433 PMID:30876886 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL6 protein] results in increased activity of CASP3 protein
trovafloxacin promotes the reaction [TNF protein results in increased expression of IL6 protein]
CTD PMID:19362101 PMID:19638433 PMID:30876886 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ip6k2 inositol hexakisphosphate kinase 2 increases expression EXP trovafloxacin results in increased expression of IP6K2 mRNA CTD PMID:24136188 NCBI chr 8:117,574,136...117,599,849
Ensembl chr 8:117,574,161...117,599,848
JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions
decreases expression
ISO
EXP
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IRF1 mRNA
trovafloxacin results in decreased expression of IRF1 mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
JBrowse link
G Isg20 interferon stimulated exonuclease gene 20 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ISG20 mRNA CTD PMID:18930950 NCBI chr 1:140,602,553...140,608,892
Ensembl chr 1:140,601,791...140,608,946
JBrowse link
G Ist1 IST1 factor associated with ESCRT-III increases expression EXP trovafloxacin results in increased expression of IST1 mRNA CTD PMID:24136188 NCBI chr19:41,968,692...41,990,843
Ensembl chr19:41,968,705...41,990,843
JBrowse link
G Ivns1abp influenza virus NS1A binding protein multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IVNS1ABP mRNA CTD PMID:18930950 NCBI chr13:68,702,970...68,722,472
Ensembl chr13:68,702,820...68,722,472
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of JUNB mRNA CTD PMID:18930950 NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
JBrowse link
G Klf9 Kruppel-like factor 9 increases expression EXP trovafloxacin results in increased expression of KLF9 mRNA CTD PMID:24136188 NCBI chr 1:240,908,483...240,933,198
Ensembl chr 1:240,908,483...240,933,198
JBrowse link
G Klhl24 kelch-like family member 24 increases expression EXP trovafloxacin results in increased expression of KLHL24 mRNA CTD PMID:24136188 NCBI chr11:84,613,101...84,643,674
Ensembl chr11:84,615,760...84,633,504
JBrowse link
G Kpna2 karyopherin subunit alpha 2 decreases expression EXP trovafloxacin results in decreased expression of KPNA2 mRNA CTD PMID:24136188 NCBI chr10:95,200,029...95,212,111
Ensembl chr10:95,200,030...95,212,111
JBrowse link
G Kpnb1 karyopherin subunit beta 1 decreases expression EXP trovafloxacin results in decreased expression of KPNB1 mRNA CTD PMID:24136188 NCBI chr10:85,096,517...85,124,641
Ensembl chr10:85,093,841...85,124,644
JBrowse link
G Krt18 keratin 18 decreases expression EXP trovafloxacin results in decreased expression of KRT18 mRNA CTD PMID:24136188 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
JBrowse link
G Laptm4b lysosomal protein transmembrane 4 beta decreases expression EXP trovafloxacin results in decreased expression of LAPTM4B mRNA CTD PMID:24136188 NCBI chr 7:72,924,911...72,968,099
Ensembl chr 7:72,924,799...72,968,101
JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of LDLR mRNA CTD PMID:18930950 NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
JBrowse link
G Letm1 leucine zipper and EF-hand containing transmembrane protein 1 decreases expression EXP trovafloxacin results in decreased expression of LETM1 mRNA CTD PMID:24136188 NCBI chr14:82,227,790...82,267,298
Ensembl chr14:82,227,708...82,267,350
JBrowse link
G Lgalsl galectin-like decreases expression EXP trovafloxacin results in decreased expression of LGALSL mRNA CTD PMID:24136188 NCBI chr14:105,047,915...105,055,421
Ensembl chr14:105,047,919...105,055,421
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of LITAF mRNA CTD PMID:18930950 NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
JBrowse link
G Lmna lamin A/C decreases expression EXP trovafloxacin results in decreased expression of LMNA mRNA CTD PMID:24136188 NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
JBrowse link
G LOC100364500 RT1 class I, locus CE11-like multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HLA-A mRNA CTD PMID:18930950 NCBI chr20:2,704,153...2,707,111
Ensembl chr20:2,704,148...2,707,120
JBrowse link
G Lpin1 lipin 1 increases expression EXP trovafloxacin results in increased expression of LPIN1 mRNA CTD PMID:24136188 NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
JBrowse link
G Lrp6 LDL receptor related protein 6 increases expression EXP trovafloxacin results in increased expression of LRP6 mRNA CTD PMID:24136188 NCBI chr 4:168,194,054...168,323,962
Ensembl chr 4:168,194,927...168,323,751
JBrowse link
G Lsm4 LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated decreases expression EXP trovafloxacin results in decreased expression of LSM4 mRNA CTD PMID:24136188 NCBI chr16:20,506,399...20,511,818
Ensembl chr16:20,506,399...20,511,818
JBrowse link
G Lta4h leukotriene A4 hydrolase decreases expression EXP trovafloxacin results in decreased expression of LTA4H mRNA CTD PMID:24136188 NCBI chr 7:34,288,333...34,320,243
Ensembl chr 7:34,288,365...34,320,235
JBrowse link
G Lyz2 lysozyme 2 decreases expression EXP trovafloxacin results in decreased expression of LYZ2 mRNA CTD PMID:24136188 NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
JBrowse link
G Mal2 mal, T-cell differentiation protein 2 decreases expression EXP trovafloxacin results in decreased expression of MAL2 mRNA CTD PMID:24136188 NCBI chr 7:94,130,852...94,163,649
Ensembl chr 7:94,130,852...94,163,645
JBrowse link
G Manf mesencephalic astrocyte-derived neurotrophic factor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MANF mRNA CTD PMID:18930950 NCBI chr 8:115,623,175...115,626,408
Ensembl chr 8:115,623,178...115,626,380
JBrowse link
G Map2k7 mitogen activated protein kinase kinase 7 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MAP2K7 mRNA CTD PMID:18930950 NCBI chr12:2,546,278...2,555,310
Ensembl chr12:2,548,218...2,555,164
JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAP3K8 mRNA CTD PMID:18930950 NCBI chr17:56,109,403...56,129,925
Ensembl chr17:56,109,549...56,129,919
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases activity
multiple interactions
ISO trovafloxacin results in increased activity of MAPK1 protein
[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of MAPK1 protein
U 0126 inhibits the reaction [trovafloxacin results in increased activity of MAPK1 protein]
CTD PMID:24525298 PMID:32035082 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases activity
multiple interactions
ISO trovafloxacin results in increased activity of MAPK3 protein
[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of MAPK3 protein
U 0126 inhibits the reaction [trovafloxacin results in increased activity of MAPK3 protein]
CTD PMID:24525298 PMID:32035082 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 multiple interactions
increases phosphorylation
ISO SB 203580 inhibits the reaction [trovafloxacin results in increased phosphorylation of MAPKAPK2 protein] CTD PMID:24525298 NCBI chr13:47,785,157...47,871,684
Ensembl chr13:47,785,161...47,831,110
JBrowse link
G Mavs mitochondrial antiviral signaling protein multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MAVS mRNA CTD PMID:18930950 NCBI chr 3:123,776,147...123,790,572
Ensembl chr 3:123,776,181...123,790,567
JBrowse link
G Mdh2 malate dehydrogenase 2 decreases expression EXP trovafloxacin results in decreased expression of MDH2 mRNA CTD PMID:24136188 NCBI chr12:23,941,451...23,954,406
Ensembl chr12:23,941,448...23,954,431
JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MDM2 mRNA CTD PMID:18930950 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Me1 malic enzyme 1 decreases expression EXP trovafloxacin results in decreased expression of ME1 mRNA CTD PMID:24136188 NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
JBrowse link
G Med20 mediator complex subunit 20 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MED20 mRNA CTD PMID:18930950 NCBI chr 9:15,379,379...15,393,131
Ensembl chr 9:15,379,385...15,393,131
JBrowse link
G Memo1 mediator of cell motility 1 decreases expression EXP trovafloxacin results in decreased expression of MEMO1 mRNA CTD PMID:24136188 NCBI chr 6:22,362,483...22,409,583
Ensembl chr 6:22,362,484...22,409,579
JBrowse link
G Mgll monoglyceride lipase decreases expression EXP trovafloxacin results in decreased expression of MGLL mRNA CTD PMID:24136188 NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
JBrowse link
G Mir877 microRNA 877 increases expression ISO trovafloxacin results in increased expression of MIR877 mRNA CTD PMID:27713024 NCBI chr20:3,318,872...3,318,956
Ensembl chr20:3,318,872...3,318,956
JBrowse link
G Mlxipl MLX interacting protein-like multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MLXIPL mRNA CTD PMID:18930950 NCBI chr12:24,590,645...24,619,639 JBrowse link
G Mmp13 matrix metallopeptidase 13 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MMP13 mRNA CTD PMID:18930950 NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
JBrowse link
G Mogs mannosyl-oligosaccharide glucosidase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MOGS mRNA CTD PMID:18930950 NCBI chr 4:113,948,328...113,951,731
Ensembl chr 4:113,948,514...113,951,847
JBrowse link
G Mphosph8 M-phase phosphoprotein 8 increases expression EXP trovafloxacin results in increased expression of MPHOSPH8 mRNA CTD PMID:24136188 NCBI chr15:36,918,843...36,946,712
Ensembl chr15:36,918,843...36,946,708
JBrowse link
G Mrpl12 mitochondrial ribosomal protein L12 decreases expression EXP trovafloxacin results in decreased expression of MRPL12 mRNA CTD PMID:24136188 NCBI chr10:109,658,032...109,662,535
Ensembl chr10:109,658,032...109,662,535
JBrowse link
G Mrps18b mitochondrial ribosomal protein S18B decreases expression EXP trovafloxacin results in decreased expression of MRPS18B mRNA CTD PMID:24136188 NCBI chr20:3,344,870...3,350,929
Ensembl chr20:3,344,870...3,350,927
JBrowse link
G Mt1 metallothionein 1 increases expression EXP trovafloxacin results in increased expression of MT1A mRNA CTD PMID:24136188 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
JBrowse link
G Mttp microsomal triglyceride transfer protein decreases expression EXP trovafloxacin results in decreased expression of MTTP mRNA CTD PMID:24136188 NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MYD88 mRNA CTD PMID:18930950 NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
JBrowse link
G Naa15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit decreases expression EXP trovafloxacin results in decreased expression of NAA15 mRNA CTD PMID:24136188 NCBI chr 2:140,471,437...140,534,259
Ensembl chr 2:140,471,690...140,534,259
JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 decreases expression EXP trovafloxacin results in decreased expression of NDUFAF4 mRNA CTD PMID:24136188 NCBI chr 5:39,251,370...39,256,542
Ensembl chr 5:39,251,337...39,257,512
JBrowse link
G Nedd4l NEDD4 like E3 ubiquitin protein ligase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NEDD4L mRNA CTD PMID:18930950 NCBI chr18:60,392,376...60,719,720
Ensembl chr18:60,392,376...60,719,720
JBrowse link
G Nedd9 neural precursor cell expressed, developmentally down-regulated 9 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NEDD9 mRNA CTD PMID:18930950 NCBI chr17:22,984,792...23,179,701
Ensembl chr17:22,984,844...23,179,701
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
increases expression
ISO [Lipopolysaccharides co-treated with trovafloxacin] results in increased expression of NFKBIA mRNA; [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFKBIA mRNA; [trovafloxacin co-treated with TNF protein] results in decreased expression of NFKBIA protein; trovafloxacin promotes the reaction [TNF protein results in increased expression of NFKBIA mRNA]
[trovafloxacin co-treated with TNF protein] results in increased expression of NFKBIA mRNA
trovafloxacin results in increased expression of NFKBIA mRNA; trovafloxacin results in increased expression of NFKBIA protein
CTD PMID:18930950 PMID:32035082 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nfkbiz NFKB inhibitor zeta multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFKBIZ mRNA CTD PMID:18930950 NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487
JBrowse link
G Nme1 NME/NM23 nucleoside diphosphate kinase 1 decreases expression EXP trovafloxacin results in decreased expression of NME1 mRNA CTD PMID:24136188 NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
JBrowse link
G Nme2 NME/NM23 nucleoside diphosphate kinase 2 decreases expression EXP trovafloxacin results in decreased expression of NME2 mRNA CTD PMID:24136188 NCBI chr10:81,648,216...81,653,717
Ensembl chr10:81,648,216...81,653,717
JBrowse link
G Noct nocturnin multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NOCT mRNA CTD PMID:18930950 NCBI chr 2:140,286,661...140,306,869
Ensembl chr 2:140,286,661...140,306,869
JBrowse link
G Notch2 notch receptor 2 decreases expression EXP trovafloxacin results in decreased expression of NOTCH2 mRNA CTD PMID:24136188 NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
JBrowse link
G Nr2f6 nuclear receptor subfamily 2, group F, member 6 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of NR2F6 mRNA CTD PMID:18930950 NCBI chr16:19,769,968...19,777,414
Ensembl chr16:19,769,968...19,777,414
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases expression EXP trovafloxacin results in increased expression of NR3C1 mRNA CTD PMID:24136188 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Nudt7 nudix hydrolase 7 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of NUDT7 mRNA CTD PMID:18930950 NCBI chr19:46,455,745...46,470,070
Ensembl chr19:46,455,761...46,482,050
JBrowse link
G Nup98 nucleoporin 98 and 96 precursor increases expression EXP trovafloxacin results in increased expression of NUP98 mRNA CTD PMID:24136188 NCBI chr 1:167,213,866...167,308,851
Ensembl chr 1:167,213,866...167,308,851
JBrowse link
G Obp3 alpha-2u globulin PGCL4 increases expression EXP trovafloxacin results in increased expression of OBP3 mRNA CTD PMID:24136188 NCBI chr 5:77,313,357...77,316,875 JBrowse link
G P2ry2 purinergic receptor P2Y2 decreases expression EXP trovafloxacin results in decreased expression of P2RY2 mRNA CTD PMID:24136188 NCBI chr 1:166,031,228...166,045,423
Ensembl chr 1:166,031,272...166,037,424
JBrowse link
G Pacsin2 protein kinase C and casein kinase substrate in neurons 2 decreases expression EXP trovafloxacin results in decreased expression of PACSIN2 mRNA CTD PMID:24136188 NCBI chr 7:124,224,210...124,317,407
Ensembl chr 7:124,223,633...124,317,379
JBrowse link
G Pbld1 phenazine biosynthesis-like protein domain containing 1 increases expression EXP trovafloxacin results in increased expression of PBLD1 mRNA CTD PMID:24136188 NCBI chr20:27,103,300...27,118,650
Ensembl chr20:27,103,317...27,117,663
JBrowse link
G Pcsk6 proprotein convertase subtilisin/kexin type 6 decreases expression EXP trovafloxacin results in decreased expression of PCSK6 mRNA CTD PMID:24136188 NCBI chr 1:126,749,508...126,947,392
Ensembl chr 1:126,749,508...126,947,392
JBrowse link
G Pctp phosphatidylcholine transfer protein decreases expression EXP trovafloxacin results in decreased expression of PCTP mRNA CTD PMID:24136188 NCBI chr10:77,491,445...77,537,268
Ensembl chr10:77,491,454...77,512,032
JBrowse link
G Pde4b phosphodiesterase 4B decreases expression
multiple interactions
EXP
ISO
trovafloxacin results in decreased expression of PDE4B mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PDE4B mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr 5:121,759,236...122,136,814
Ensembl chr 5:121,952,977...122,136,814
JBrowse link
G Pdhx pyruvate dehydrogenase complex, component X decreases expression EXP trovafloxacin results in decreased expression of PDHX mRNA CTD PMID:24136188 NCBI chr 3:92,910,300...92,933,725
Ensembl chr 3:92,909,725...92,969,050
JBrowse link
G Pdlim1 PDZ and LIM domain 1 decreases expression EXP trovafloxacin results in decreased expression of PDLIM1 mRNA CTD PMID:24136188 NCBI chr 1:259,308,326...259,357,006
Ensembl chr 1:259,308,296...259,357,056
JBrowse link
G Perp p53 apoptosis effector related to PMP22 decreases expression EXP trovafloxacin results in decreased expression of PERP mRNA CTD PMID:24136188 NCBI chr 1:14,224,392...14,236,838
Ensembl chr 1:14,224,393...14,236,846
JBrowse link
G Pex2 peroxisomal biogenesis factor 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PEX2 mRNA CTD PMID:18930950 NCBI chr 2:98,251,756...98,269,185
Ensembl chr 2:98,252,925...98,269,184
JBrowse link
G Pgk1 phosphoglycerate kinase 1 decreases expression EXP trovafloxacin results in decreased expression of PGK1 mRNA CTD PMID:24136188 NCBI chr  X:77,263,399...77,279,373
Ensembl chr  X:77,263,359...77,279,367
JBrowse link
G Pgm1 phosphoglucomutase 1 decreases expression EXP trovafloxacin results in decreased expression of PGM1 mRNA CTD PMID:24136188 NCBI chr 5:118,743,632...118,803,055
Ensembl chr 5:118,743,632...118,803,055
JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PHLDA1 mRNA CTD PMID:18930950 NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
JBrowse link
G Pink1 PTEN induced kinase 1 increases expression EXP trovafloxacin results in increased expression of PINK1 mRNA CTD PMID:24136188 NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
JBrowse link
G Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PIP5K1A mRNA CTD PMID:18930950 NCBI chr 2:196,227,669...196,270,949
Ensembl chr 2:196,227,670...196,270,826
JBrowse link
G Pisd phosphatidylserine decarboxylase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PISD mRNA CTD PMID:18930950 NCBI chr14:83,298,630...83,347,697
Ensembl chr14:83,298,674...83,346,738
JBrowse link
G Plbd1 phospholipase B domain containing 1 decreases expression EXP trovafloxacin results in decreased expression of PLBD1 mRNA CTD PMID:24136188 NCBI chr 4:170,564,387...170,620,681
Ensembl chr 4:170,564,367...170,620,703
JBrowse link
G Plin2 perilipin 2 decreases expression EXP trovafloxacin results in decreased expression of PLIN2 mRNA CTD PMID:24136188 NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
JBrowse link
G Plin3 perilipin 3 decreases expression EXP trovafloxacin results in decreased expression of PLIN3 mRNA CTD PMID:24136188 NCBI chr 9:10,769,739...10,781,659
Ensembl chr 9:10,773,901...10,781,109
JBrowse link
G Plk3 polo-like kinase 3 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PLK3 mRNA CTD PMID:18930950 NCBI chr 5:135,997,725...136,002,900
Ensembl chr 5:135,997,725...136,002,900
JBrowse link
G Plpp3 phospholipid phosphatase 3 increases expression EXP trovafloxacin results in increased expression of PLPP3 mRNA CTD PMID:24136188 NCBI chr 5:124,690,214...124,765,499
Ensembl chr 5:124,690,214...124,765,498
JBrowse link
G Pnp purine nucleoside phosphorylase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PNP2 mRNA CTD PMID:18930950 NCBI chr15:27,875,883...27,883,566
Ensembl chr15:27,875,911...27,883,350
JBrowse link
G Polrmt RNA polymerase mitochondrial multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of POLRMT mRNA CTD PMID:18930950 NCBI chr 7:12,840,907...12,851,153
Ensembl chr 7:12,840,938...12,851,153
JBrowse link
G Ppa1 inorganic pyrophosphatase 1 decreases expression EXP trovafloxacin results in decreased expression of PPA1 mRNA CTD PMID:24136188 NCBI chr20:31,265,519...31,292,451
Ensembl chr20:31,265,483...31,310,674
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases expression ISO trovafloxacin results in decreased expression of PPARA mRNA CTD PMID:25689681 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Ppox protoporphyrinogen oxidase decreases expression EXP trovafloxacin results in decreased expression of PPOX mRNA CTD PMID:24136188 NCBI chr13:89,650,094...89,654,998
Ensembl chr13:89,650,094...89,654,244
JBrowse link
G Ppp1r14a protein phosphatase 1, regulatory (inhibitor) subunit 14A decreases expression EXP trovafloxacin results in decreased expression of PPP1R14A mRNA CTD PMID:24136188 NCBI chr 1:87,224,683...87,232,842
Ensembl chr 1:87,224,677...87,232,848
JBrowse link
G Ppp1r14b protein phosphatase 1, regulatory (inhibitor) subunit 14B decreases expression EXP trovafloxacin results in decreased expression of PPP1R14B mRNA CTD PMID:24136188 NCBI chr 1:222,229,835...222,231,945
Ensembl chr 1:222,229,835...222,231,944
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PPP1R15A mRNA CTD PMID:18930950 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Preb prolactin regulatory element binding multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PREB mRNA CTD PMID:18930950 NCBI chr 6:26,784,088...26,787,875
Ensembl chr 6:26,784,088...26,787,874
JBrowse link
G Proser2 proline and serine rich 2 increases expression EXP trovafloxacin results in increased expression of PROSER2 mRNA CTD PMID:24136188 NCBI chr17:76,079,641...76,140,428
Ensembl chr17:76,079,720...76,137,697
JBrowse link
G Prss23 serine protease 23 decreases expression EXP trovafloxacin results in decreased expression of PRSS23 mRNA CTD PMID:24136188 NCBI chr 1:153,732,528...153,742,111
Ensembl chr 1:153,732,532...153,752,541
JBrowse link
G Psma5 proteasome 20S subunit alpha 5 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PSMA5 mRNA CTD PMID:18930950 NCBI chr 2:211,050,344...211,073,706
Ensembl chr 2:211,050,360...211,073,714
JBrowse link
G Psmb10 proteasome 20S subunit beta 10 decreases expression EXP trovafloxacin results in decreased expression of PSMB10 mRNA CTD PMID:24136188 NCBI chr19:37,909,543...37,912,027
Ensembl chr19:37,909,546...37,912,027
JBrowse link
G Pten phosphatase and tensin homolog multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTEN mRNA CTD PMID:18930950 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Ptgr2 prostaglandin reductase 2 decreases expression EXP trovafloxacin results in decreased expression of PTGR2 mRNA CTD PMID:24136188 NCBI chr 6:107,999,832...108,031,645
Ensembl chr 6:107,999,846...108,031,643
JBrowse link
G Ptma prothymosin alpha decreases expression EXP trovafloxacin results in decreased expression of PTMA mRNA CTD PMID:24136188 NCBI chr 9:93,545,396...93,549,436
Ensembl chr 9:93,545,396...93,549,436
JBrowse link
G Ptp4a1 protein tyrosine phosphatase 4A1 increases expression
multiple interactions
EXP
ISO
trovafloxacin results in increased expression of PTP4A1 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTP4A1 mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr 9:37,223,363...37,254,222
Ensembl chr 9:37,223,729...37,231,291
JBrowse link
G Ptpn2 protein tyrosine phosphatase, non-receptor type 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTPN2 mRNA CTD PMID:18930950 NCBI chr18:63,415,298...63,489,240
Ensembl chr18:63,415,306...63,488,027
JBrowse link
G Ptpn21 protein tyrosine phosphatase, non-receptor type 21 decreases expression EXP trovafloxacin results in decreased expression of PTPN21 mRNA CTD PMID:24136188 NCBI chr 6:122,656,500...122,721,496
Ensembl chr 6:122,656,500...122,721,496
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin decreases expression EXP trovafloxacin results in decreased expression of PTTG1 mRNA CTD PMID:24136188 NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
JBrowse link
G Ran RAN, member RAS oncogene family decreases expression EXP trovafloxacin results in decreased expression of RAN mRNA CTD PMID:24136188 NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
JBrowse link
G Rangap1 RAN GTPase activating protein 1 decreases expression EXP trovafloxacin results in decreased expression of RANGAP1 mRNA CTD PMID:24136188 NCBI chr 7:122,939,266...122,967,178
Ensembl chr 7:122,940,376...122,967,178
JBrowse link
G Rarb retinoic acid receptor, beta decreases expression EXP trovafloxacin results in decreased expression of RARB mRNA CTD PMID:24136188 NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression EXP trovafloxacin results in decreased expression of RB1 mRNA CTD PMID:24136188 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rcan1 regulator of calcineurin 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of RCAN1 mRNA CTD PMID:18930950 NCBI chr11:32,539,689...32,620,274
Ensembl chr11:32,539,683...32,550,539
JBrowse link
G Rdx radixin multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RDX mRNA CTD PMID:18930950 NCBI chr 8:56,570,728...56,612,851
Ensembl chr 8:56,585,396...56,610,612
JBrowse link
G Reep6 receptor accessory protein 6 decreases expression EXP trovafloxacin results in decreased expression of REEP6 mRNA CTD PMID:24136188 NCBI chr 7:12,240,059...12,246,814
Ensembl chr 7:12,240,060...12,246,729
JBrowse link
G Rel REL proto-oncogene, NF-kB subunit multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of REL mRNA CTD PMID:18930950 NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
affects localization
ISO trovafloxacin affects the reaction [TNF protein affects the localization of RELA protein modified form]; trovafloxacin affects the reaction [TNF protein results in increased phosphorylation of RELA protein]
trovafloxacin affects the localization of RELA protein
trovafloxacin affects the reaction [Lipopolysaccharides affects the localization of RELA protein]
CTD PMID:32035082 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G RGD1308742 similar to Complement C5 precursor increases expression EXP trovafloxacin results in increased expression of RGD1308742 mRNA CTD PMID:24136188 NCBI chr 3:14,273,552...14,291,401
Ensembl chr 3:14,276,280...14,291,343
JBrowse link
G RGD1309534 similar to RIKEN cDNA 4931406C07 decreases expression EXP trovafloxacin results in decreased expression of RGD1309534 mRNA CTD PMID:24136188 NCBI chr 8:13,838,549...13,861,120
Ensembl chr 8:13,838,572...13,861,212
JBrowse link
G RGD1564804 similar to chromosome 1 open reading frame 50 increases expression EXP trovafloxacin results in increased expression of RGD1564804 mRNA CTD PMID:24136188 NCBI chr 5:138,274,907...138,279,285
Ensembl chr 5:138,274,907...138,279,285
JBrowse link
G Rmdn2 regulator of microtubule dynamics 2 decreases expression EXP trovafloxacin results in decreased expression of RMDN2 mRNA CTD PMID:24136188 NCBI chr 6:2,215,062...2,292,288
Ensembl chr 6:2,216,623...2,280,777
JBrowse link
G Rnd3 Rho family GTPase 3 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of RND3 mRNA CTD PMID:18930950 NCBI chr 3:36,643,374...36,660,727
Ensembl chr 3:36,642,587...36,660,758
JBrowse link
G Rnf26 ring finger protein 26 decreases expression EXP trovafloxacin results in decreased expression of RNF26 mRNA CTD PMID:24136188 NCBI chr 8:48,447,113...48,449,311
Ensembl chr 8:48,447,113...48,449,311
JBrowse link
G Rnf39 ring finger protein 39 increases expression EXP trovafloxacin results in increased expression of RNF39 mRNA CTD PMID:24136188 NCBI chr20:2,098,375...2,103,864
Ensembl chr20:2,098,375...2,103,864
JBrowse link
G Rnf6 ring finger protein 6 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RNF6 mRNA CTD PMID:18930950 NCBI chr12:10,574,168...10,583,196
Ensembl chr12:10,574,168...10,583,208
JBrowse link
G Rpa1 replication protein A1 decreases expression EXP trovafloxacin results in decreased expression of RPA1 mRNA CTD PMID:24136188 NCBI chr10:62,140,419...62,191,518
Ensembl chr10:62,140,419...62,191,512
JBrowse link
G Rpl7l1 ribosomal protein L7-like 1 decreases expression EXP trovafloxacin results in decreased expression of RPL7L1 mRNA CTD PMID:24136188 NCBI chr 9:16,508,477...16,516,502
Ensembl chr 9:16,508,799...16,513,120
JBrowse link
G Rrm2 ribonucleotide reductase regulatory subunit M2 decreases expression EXP trovafloxacin results in decreased expression of RRM2 mRNA CTD PMID:24136188 NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
JBrowse link
G Rsrp1 arginine and serine rich protein 1 increases expression EXP trovafloxacin results in increased expression of RSRP1 mRNA CTD PMID:24136188 NCBI chr 5:153,260,930...153,264,669
Ensembl chr 5:153,260,930...153,264,669
JBrowse link
G S100a11 S100 calcium binding protein A11 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of S100A11 mRNA CTD PMID:18930950 NCBI chr 2:193,863,185...193,868,646
Ensembl chr 2:193,866,951...193,868,502
JBrowse link
G Sae1 SUMO1 activating enzyme subunit 1 decreases expression EXP trovafloxacin results in decreased expression of SAE1 mRNA CTD PMID:24136188 NCBI chr 1:78,277,524...78,333,281
Ensembl chr 1:78,277,515...78,333,321
JBrowse link
G Sarnp SAP domain containing ribonucleoprotein decreases expression EXP trovafloxacin results in decreased expression of SARNP mRNA CTD PMID:24136188 NCBI chr 7:3,246,220...3,300,467
Ensembl chr 7:3,246,220...3,300,455
JBrowse link
G Sat1 spermidine/spermine N1-acetyl transferase 1 increases expression EXP trovafloxacin results in increased expression of SAT1 mRNA CTD PMID:24136188 NCBI chr  X:43,626,480...43,629,767
Ensembl chr  X:43,625,169...43,629,765
JBrowse link
G Scd stearoyl-CoA desaturase decreases expression EXP trovafloxacin results in decreased expression of SCD1 mRNA CTD PMID:24136188 NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
JBrowse link
G Sds serine dehydratase increases expression EXP trovafloxacin results in increased expression of SDS mRNA CTD PMID:24136188 NCBI chr12:41,620,429...41,627,741
Ensembl chr12:41,620,393...41,627,741
JBrowse link
G Sec24d SEC24 homolog D, COPII coat complex component decreases expression EXP trovafloxacin results in decreased expression of SEC24D mRNA CTD PMID:24136188 NCBI chr 2:227,455,704...227,562,801
Ensembl chr 2:227,455,722...227,562,319
JBrowse link
G Sele selectin E multiple interactions ISO [trovafloxacin co-treated with IL1B protein] affects the localization of SELE protein; [trovafloxacin co-treated with IL1B protein] results in increased expression of SELE mRNA; trovafloxacin promotes the reaction [IL1B protein results in increased secretion of SELE protein]
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SELE mRNA
CTD PMID:10822086 PMID:18930950 NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
JBrowse link
G Senp2 SUMO specific peptidase 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SENP2 mRNA CTD PMID:18930950 NCBI chr11:82,627,973...82,664,702
Ensembl chr11:82,630,436...82,664,630
JBrowse link
G Serpina3m serpin family A member 3M multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SERPINA3 mRNA CTD PMID:18930950 NCBI chr 6:127,808,785...127,816,067
Ensembl chr 6:127,808,785...127,816,055
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SERPINE1 mRNA; SERPINE1 protein results in increased susceptibility to [trovafloxacin co-treated with Lipopolysaccharides]; trovafloxacin promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein] CTD PMID:18930950 PMID:19367693 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sf3a3 splicing factor 3a, subunit 3 decreases expression EXP trovafloxacin results in decreased expression of SF3A3 mRNA CTD PMID:24136188 NCBI chr 5:142,702,721...142,722,350
Ensembl chr 5:142,702,685...142,722,341
JBrowse link
G Sfpq splicing factor proline and glutamine rich decreases expression EXP trovafloxacin results in decreased expression of SFPQ mRNA CTD PMID:24136188 NCBI chr 5:145,079,803...145,088,517
Ensembl chr 5:145,079,803...145,088,498
JBrowse link
G Sh3bp5 SH3-domain binding protein 5 increases expression EXP trovafloxacin results in increased expression of SH3BP5 mRNA CTD PMID:24136188 NCBI chr16:7,473,367...7,559,976
Ensembl chr16:7,473,370...7,538,201
JBrowse link
G Skil SKI-like proto-oncogene multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SKIL mRNA CTD PMID:18930950 NCBI chr 2:115,862,932...115,891,304
Ensembl chr 2:115,866,701...115,891,097
JBrowse link
G Slc11a2 solute carrier family 11 member 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SLC11A2 mRNA CTD PMID:18930950 NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
JBrowse link
G Slc17a2 solute carrier family 17, member 2 increases expression EXP trovafloxacin results in increased expression of SLC17A2 mRNA CTD PMID:24136188 NCBI chr17:43,567,528...43,584,228
Ensembl chr17:43,567,528...43,584,152
JBrowse link
G Slc17a3 solute carrier family 17 member 3 decreases expression
multiple interactions
EXP
ISO
trovafloxacin results in decreased expression of SLC17A3 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SLC17A3 mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr17:43,518,760...43,545,160
Ensembl chr17:43,518,655...43,543,185
JBrowse link
G Slc22a1 solute carrier family 22 member 1 decreases expression EXP trovafloxacin results in decreased expression of SLC22A1 mRNA CTD PMID:24136188 NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
JBrowse link
G Slc34a2 solute carrier family 34 member 2 decreases expression EXP trovafloxacin results in decreased expression of SLC34A2 mRNA CTD PMID:24136188 NCBI chr14:60,257,211...60,276,516
Ensembl chr14:60,256,712...60,276,794
JBrowse link
G Slc35e3 solute carrier family 35, member E3 decreases expression EXP trovafloxacin results in decreased expression of SLC35E3 mRNA CTD PMID:24136188 NCBI chr 7:60,765,077...60,778,136
Ensembl chr 7:60,765,079...60,778,136
JBrowse link
G Slc39a14 solute carrier family 39 member 14 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SLC39A14 mRNA CTD PMID:18930950 NCBI chr15:51,982,872...52,029,841
Ensembl chr15:51,982,982...52,029,816
JBrowse link
G Slc41a2 solute carrier family 41 member 2 decreases expression EXP trovafloxacin results in decreased expression of SLC41A2 mRNA CTD PMID:24136188 NCBI chr 7:26,522,314...26,607,861
Ensembl chr 7:26,522,314...26,607,861
JBrowse link
G Slc46a1 solute carrier family 46 member 1 increases expression EXP trovafloxacin results in increased expression of SLC46A1 mRNA CTD PMID:24136188 NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
JBrowse link
G Slc7a2 solute carrier family 7 member 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SLC7A2 mRNA CTD PMID:18930950 NCBI chr16:54,459,409...54,513,349
Ensembl chr16:54,460,067...54,513,349
JBrowse link
G Slc9a3r1 SLC9A3 regulator 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SLC9A3R1 mRNA CTD PMID:18930950 NCBI chr10:103,713,045...103,730,145
Ensembl chr10:103,713,045...103,730,145
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression EXP trovafloxacin results in increased expression of SLCO1A2 mRNA CTD PMID:24136188 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SLCO1B3 mRNA CTD PMID:18930950 NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
JBrowse link
G Smarcd2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SMARCD2 mRNA CTD PMID:18930950 NCBI chr10:94,451,866...94,460,732
Ensembl chr10:94,451,866...94,460,732
JBrowse link
G Smndc1 survival motor neuron domain containing 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SMNDC1 mRNA CTD PMID:18930950 NCBI chr 1:274,096,068...274,107,138
Ensembl chr 1:274,096,068...274,107,138
JBrowse link
G Snd1 staphylococcal nuclease and tudor domain containing 1 decreases expression EXP trovafloxacin results in decreased expression of SND1 mRNA CTD PMID:24136188 NCBI chr 4:55,772,377...56,171,669
Ensembl chr 4:55,772,377...56,171,668
JBrowse link
G Socs2 suppressor of cytokine signaling 2 increases expression
multiple interactions
EXP
ISO
trovafloxacin results in increased expression of SOCS2 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SOCS2 mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr 7:36,495,496...36,500,878
Ensembl chr 7:36,495,480...36,499,784
JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SOCS3 mRNA CTD PMID:18930950 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SOD2 mRNA CTD PMID:18930950 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Spart spartin decreases expression EXP trovafloxacin results in decreased expression of SPG20 mRNA CTD PMID:24136188 NCBI chr 2:144,522,382...144,548,968
Ensembl chr 2:144,522,072...144,548,917
JBrowse link
G Spred2 sprouty-related, EVH1 domain containing 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SPRED2 mRNA CTD PMID:18930950 NCBI chr14:104,268,362...104,290,206
Ensembl chr14:104,191,517...104,290,456
JBrowse link
G Sptssa serine palmitoyltransferase, small subunit A increases expression EXP trovafloxacin results in increased expression of SPTSSA mRNA CTD PMID:24136188 NCBI chr 6:75,540,132...75,551,545
Ensembl chr 6:75,540,174...75,551,625
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression EXP trovafloxacin results in decreased expression of SREBF1 mRNA CTD PMID:24136188 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Srm spermidine synthase decreases expression EXP trovafloxacin results in decreased expression of SRM mRNA CTD PMID:24136188 NCBI chr 5:165,405,168...165,408,325
Ensembl chr 5:165,405,168...165,408,320
JBrowse link
G Srp72 signal recognition particle 72 decreases expression EXP trovafloxacin results in decreased expression of SRP72 mRNA CTD PMID:24136188 NCBI chr14:33,447,583...33,453,788 JBrowse link
G Srrm2 serine/arginine repetitive matrix 2 increases expression EXP trovafloxacin results in increased expression of SRRM2 mRNA CTD PMID:24136188 NCBI chr10:13,128,820...13,162,956
Ensembl chr10:13,145,099...13,162,343
JBrowse link
G Srsf1 serine and arginine rich splicing factor 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SRSF1 mRNA CTD PMID:18930950 NCBI chr10:75,334,200...75,341,197
Ensembl chr10:75,335,146...75,341,197
JBrowse link
G Srsf2 serine and arginine rich splicing factor 2 decreases expression
multiple interactions
EXP
ISO
trovafloxacin results in decreased expression of SRSF2 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SRSF2 mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr10:105,792,779...105,795,986
Ensembl chr10:105,792,779...105,795,958
JBrowse link
G Srsf3 serine and arginine rich splicing factor 3 decreases expression EXP trovafloxacin results in decreased expression of SRSF3 mRNA CTD PMID:24136188 NCBI chr20:6,288,285...6,298,218
Ensembl chr20:6,288,267...6,298,213
JBrowse link
G Srsf4 serine and arginine rich splicing factor 4 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SRSF4 mRNA CTD PMID:18930950 NCBI chr 5:150,032,999...150,060,769
Ensembl chr 5:150,032,999...150,060,765
JBrowse link
G Srsf5 serine and arginine rich splicing factor 5 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SRSF5 mRNA CTD PMID:18930950 NCBI chr 6:104,611,026...104,640,033
Ensembl chr 6:104,611,026...104,615,302
JBrowse link
G Ssx2ip SSX family member 2 interacting protein decreases expression EXP trovafloxacin results in decreased expression of SSX2IP mRNA CTD PMID:24136188 NCBI chr 2:252,263,323...252,296,049
Ensembl chr 2:252,263,386...252,296,051
JBrowse link
G Stag2 stromal antigen 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of STAG2 mRNA CTD PMID:18930950 NCBI chr  X:128,493,603...128,624,418
Ensembl chr  X:128,493,614...128,624,418
JBrowse link
G Stard4 StAR-related lipid transfer domain containing 4 increases expression EXP trovafloxacin results in increased expression of STARD4 mRNA CTD PMID:24136188 NCBI chr18:25,982,210...25,997,555
Ensembl chr18:25,984,638...25,997,555
JBrowse link
G Stard5 StAR-related lipid transfer domain containing 5 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of STARD5 mRNA CTD PMID:18930950 NCBI chr 1:145,770,135...145,780,001
Ensembl chr 1:145,770,135...145,780,001
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of STAT3 mRNA CTD PMID:18930950 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stbd1 starch binding domain 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of STBD1 mRNA CTD PMID:18930950 NCBI chr14:16,976,355...16,979,760
Ensembl chr14:16,976,356...16,979,760
JBrowse link
G Stip1 stress-induced phosphoprotein 1 decreases expression EXP trovafloxacin results in decreased expression of STIP1 mRNA CTD PMID:24136188 NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
JBrowse link
G Stmn1 stathmin 1 decreases expression EXP trovafloxacin results in decreased expression of STMN1 mRNA CTD PMID:24136188 NCBI chr 5:152,680,412...152,686,807
Ensembl chr 5:152,680,407...152,686,806
JBrowse link
G Sts steroid sulfatase increases expression EXP trovafloxacin results in increased expression of STS mRNA CTD PMID:24136188 NCBI chr  X:45,420,418...45,428,748
Ensembl chr  X:45,420,596...45,428,750
JBrowse link
G Sumo2 small ubiquitin-like modifier 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of SUMO2 mRNA CTD PMID:18930950 NCBI chr10:104,085,401...104,097,983
Ensembl chr10:104,086,002...104,097,812
JBrowse link
G Syncrip synaptotagmin binding, cytoplasmic RNA interacting protein multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of SYNCRIP mRNA CTD PMID:18930950 NCBI chr 8:96,100,692...96,266,342
Ensembl chr 8:96,105,025...96,266,342
JBrowse link
G Synrg synergin, gamma increases expression EXP trovafloxacin results in increased expression of SYNRG mRNA CTD PMID:24136188 NCBI chr10:71,278,698...71,357,791 JBrowse link
G Tat tyrosine aminotransferase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TAT mRNA CTD PMID:18930950 NCBI chr19:41,675,639...41,686,195
Ensembl chr19:41,675,355...41,686,229
JBrowse link
G Tbc1d14 TBC1 domain family, member 14 increases expression EXP trovafloxacin results in increased expression of TBC1D14 mRNA CTD PMID:24136188 NCBI chr14:79,172,272...79,438,765
Ensembl chr14:79,205,466...79,438,764
JBrowse link
G Tcirg1 T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3 decreases expression EXP trovafloxacin results in decreased expression of TCIRG1 mRNA CTD PMID:24136188 NCBI chr 1:219,126,687...219,139,466
Ensembl chr 1:219,127,602...219,139,464
JBrowse link
G Tent2 terminal nucleotidyltransferase 2 decreases expression EXP trovafloxacin results in decreased expression of TENT2 mRNA CTD PMID:24136188 NCBI chr 2:22,746,290...22,798,252
Ensembl chr 2:22,747,547...22,798,214
JBrowse link
G Tfdp1 transcription factor Dp-1 decreases expression EXP trovafloxacin results in decreased expression of TFDP1 mRNA CTD PMID:24136188 NCBI chr16:81,088,642...81,127,244
Ensembl chr16:81,089,292...81,127,257
JBrowse link
G Tfg trafficking from ER to golgi regulator multiple interactions
decreases expression
ISO
EXP
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of TFG mRNA
trovafloxacin results in decreased expression of TFG mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr11:46,180,189...46,206,723
Ensembl chr11:46,179,940...46,206,721
JBrowse link
G Tgif1 TGFB-induced factor homeobox 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TGIF1 mRNA CTD PMID:18930950 NCBI chr 9:119,181,079...119,190,698
Ensembl chr 9:119,181,083...119,190,698
JBrowse link
G Tgm2 transglutaminase 2 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TGM2 mRNA CTD PMID:18930950 NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
JBrowse link
G Thbs1 thrombospondin 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of THBS1 mRNA CTD PMID:18930950 NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
JBrowse link
G Thrap3 thyroid hormone receptor associated protein 3 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of THRAP3 mRNA CTD PMID:18930950 NCBI chr 5:144,178,248...144,221,318
Ensembl chr 5:144,179,023...144,221,263
JBrowse link
G Thrsp thyroid hormone responsive decreases expression EXP trovafloxacin results in decreased expression of THRSP mRNA CTD PMID:24136188 NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
JBrowse link
G Tkfc triokinase and FMN cyclase decreases expression EXP trovafloxacin results in decreased expression of TKFC mRNA CTD PMID:24136188 NCBI chr 1:226,642,901...226,657,698
Ensembl chr 1:226,644,200...226,657,408
JBrowse link
G Tkt transketolase decreases expression EXP trovafloxacin results in decreased expression of TKT mRNA CTD PMID:24136188 NCBI chr16:6,609,670...6,634,608
Ensembl chr16:6,609,668...6,634,595
JBrowse link
G Tle1 TLE family member 1, transcriptional corepressor increases expression EXP trovafloxacin results in increased expression of TLE1 mRNA CTD PMID:24136188 NCBI chr 5:88,546,607...88,630,277
Ensembl chr 5:88,546,568...88,629,491
JBrowse link
G Tmem106b transmembrane protein 106B increases expression EXP trovafloxacin results in increased expression of TMEM106B mRNA CTD PMID:24136188 NCBI chr 4:39,517,679...39,534,491
Ensembl chr 4:39,517,548...39,535,169
JBrowse link
G Tmem41a transmembrane protein 41a decreases expression EXP trovafloxacin results in decreased expression of TMEM41A mRNA CTD PMID:24136188 NCBI chr11:82,734,525...82,741,177
Ensembl chr11:82,734,613...82,741,428
JBrowse link
G Tmpo thymopoietin decreases expression EXP trovafloxacin results in decreased expression of TMPO mRNA CTD PMID:24136188 NCBI chr 7:31,847,412...31,872,416
Ensembl chr 7:31,847,410...31,872,423
JBrowse link
G Tmx2 thioredoxin-related transmembrane protein 2 decreases expression EXP trovafloxacin results in decreased expression of TMX2 mRNA CTD PMID:24136188 NCBI chr 3:72,073,429...72,081,079
Ensembl chr 3:72,073,431...72,081,079
JBrowse link
G Tmx4 thioredoxin-related transmembrane protein 4 increases expression EXP trovafloxacin results in increased expression of TMX4 mRNA CTD PMID:24136188 NCBI chr 3:127,528,427...127,569,093
Ensembl chr 3:127,528,434...127,569,093
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases uptake
decreases expression
increases expression
increases response to substance
increases secretion
ISO
EXP
4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of ATR protein]; [IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [TNF protein co-treated with trovafloxacin] results in increased activity of CASP3 protein; [TNF protein co-treated with trovafloxacin] results in increased expression of H2AX protein modified form; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with TNF protein] results in decreased expression of BIRC2 mRNA; [trovafloxacin co-treated with TNF protein] results in decreased expression of XIAP mRNA; [trovafloxacin co-treated with TNF protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with TNF protein] results in increased activity of CASP8 protein; [trovafloxacin co-treated with TNF protein] results in increased activity of CASP9 protein; [trovafloxacin co-treated with TNF protein] results in increased expression of BIRC3 mRNA; [trovafloxacin co-treated with TNF protein] results in increased expression of ICAM1 mRNA; [trovafloxacin co-treated with TNF protein] results in increased expression of NFKBIA mRNA; [trovafloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA; [trovafloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 protein; [trovafloxacin co-treated with TNF protein] results in increased phosphorylation of and results in increased activity of ATR protein; [trovafloxacin co-treated with TNF protein] results in increased phosphorylation of MAPK1 protein; [trovafloxacin co-treated with TNF protein] results in increased phosphorylation of MAPK3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[TNF protein co-treated with trovafloxacin] results in increased expression of H2AX protein modified form]; TNF protein promotes the reaction [trovafloxacin results in increased expression of H2AX protein modified form]; trovafloxacin affects the reaction [TNF protein affects the localization of RELA protein modified form]; trovafloxacin affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; U 0126 inhibits the reaction [[TNF protein co-treated with trovafloxacin] results in increased activity of CASP3 protein]
trovafloxacin results in decreased uptake of TNF protein
trovafloxacin results in decreased expression of TNF
trovafloxacin results in increased expression of TNF mRNA; trovafloxacin results in increased expression of TNF protein
trovafloxacin results in increased susceptibility to TNF protein
trovafloxacin results in increased secretion of TNF protein
4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased expression of and results in increased stability of TNF mRNA]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased expression of TNF protein]; [Lipopolysaccharides co-treated with trovafloxacin] results in increased expression of TNF mRNA; [Pentoxifylline results in decreased expression of TNF mRNA] results in decreased susceptibility to [lipopolysaccharide, E coli O55-B5 co-treated with trovafloxacin]; [TNF protein co-treated with trovafloxacin] results in increased cleavage of CASP3 protein; [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF protein; [trovafloxacin co-treated with TNF protein] results in decreased expression of NFKBIA protein; IFNG protein promotes the reaction [[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [trovafloxacin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; pyrazolanthrone inhibits the reaction [trovafloxacin results in increased expression of TNF mRNA]; TNF protein affects the susceptibility to [lipopolysaccharide, E coli O55-B5 co-treated with trovafloxacin]; TNF protein results in increased susceptibility to [Lipopolysaccharides co-treated with trovafloxacin]; trovafloxacin inhibits the reaction [TNF protein results in increased expression of BIRC2 mRNA]; trovafloxacin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; trovafloxacin promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; trovafloxacin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of CCL2 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of CXCL1 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of CXCL2 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IFNG protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IL18 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IL1B protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IL6 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of NFKBIA mRNA]; trovafloxacin promotes the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; trovafloxacin results in increased expression of and results in increased stability of TNF mRNA; U 0126 inhibits the reaction [trovafloxacin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; U 0126 inhibits the reaction [trovafloxacin results in increased expression of TNF mRNA]
TNF protein results in increased susceptibility to trovafloxacin
CTD PMID:17709330 PMID:18930950 PMID:19362101 PMID:19638433 PMID:24097668 PMID:24136188 PMID:24525298 PMID:24817034 PMID:25748550 PMID:30876886 PMID:32035082 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions
increases expression
ISO [Lipopolysaccharides co-treated with trovafloxacin] results in increased expression of TNFAIP3 mRNA; [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNFAIP3 mRNA; trovafloxacin promotes the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]
[trovafloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA; [trovafloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 protein
trovafloxacin results in increased expression of TNFAIP3 mRNA
trovafloxacin results in increased expression of TNFAIP3 mRNA; trovafloxacin results in increased expression of TNFAIP3 protein
CTD PMID:18930950 PMID:32035082 NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
JBrowse link
G Tob2 transducer of ERBB2, 2 increases expression EXP trovafloxacin results in increased expression of TOB2 mRNA CTD PMID:24136188 NCBI chr 7:123,079,520...123,088,240
Ensembl chr 7:123,079,537...123,088,279
JBrowse link
G Tomm70 translocase of outer mitochondrial membrane 70 decreases expression EXP trovafloxacin results in decreased expression of TOMM70A mRNA CTD PMID:24136188 NCBI chr11:45,477,053...45,511,409
Ensembl chr11:45,480,250...45,510,961
JBrowse link
G Top2a DNA topoisomerase II alpha decreases activity ISO trovafloxacin results in decreased activity of TOP2A protein CTD PMID:24817034 NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154
JBrowse link
G Tpi1 triosephosphate isomerase 1 decreases expression EXP trovafloxacin results in decreased expression of TPI1 mRNA CTD PMID:24136188 NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905
JBrowse link
G Tpm3 tropomyosin 3 decreases expression EXP trovafloxacin results in decreased expression of TPM3 mRNA CTD PMID:24136188 NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
JBrowse link
G Tpst1 tyrosylprotein sulfotransferase 1 increases expression EXP trovafloxacin results in increased expression of TPST1 mRNA CTD PMID:24136188 NCBI chr12:30,045,753...30,112,377
Ensembl chr12:30,045,751...30,106,893
JBrowse link
G Trak1 trafficking kinesin protein 1 increases expression EXP trovafloxacin results in increased expression of TRAK1 mRNA CTD PMID:24136188 NCBI chr 8:129,946,596...130,106,382
Ensembl chr 8:130,009,573...130,106,382
JBrowse link
G Ttc7a tetratricopeptide repeat domain 7A decreases expression EXP trovafloxacin results in decreased expression of TTC7A mRNA CTD PMID:24136188 NCBI chr 6:10,912,383...11,014,279
Ensembl chr 6:10,912,383...11,014,278
JBrowse link
G Tuba1c tubulin, alpha 1C decreases expression EXP trovafloxacin results in decreased expression of TUBA1C mRNA CTD PMID:24136188 NCBI chr 7:140,716,113...140,723,717
Ensembl chr 7:140,716,113...140,723,714
JBrowse link
G Tuba4a tubulin, alpha 4A decreases expression EXP trovafloxacin results in decreased expression of TUBA4A mRNA CTD PMID:24136188 NCBI chr 9:82,415,599...82,419,918
Ensembl chr 9:82,415,605...82,419,288
JBrowse link
G Tubb2a tubulin, beta 2A class IIa decreases expression EXP trovafloxacin results in decreased expression of TUBB2A mRNA CTD PMID:24136188 NCBI chr17:31,493,145...31,496,827
Ensembl chr17:31,493,107...31,498,651
JBrowse link
G Tubb4b tubulin, beta 4B class IVb multiple interactions
decreases expression
ISO
EXP
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of TUBB4B mRNA
trovafloxacin results in decreased expression of TUBB4B mRNA
CTD PMID:18930950 PMID:24136188 NCBI chr 3:2,441,585...2,444,369
Ensembl chr 3:2,441,733...2,444,281
JBrowse link
G Tubb5 tubulin, beta 5 class I decreases expression EXP trovafloxacin results in decreased expression of TUBB5 mRNA CTD PMID:24136188 NCBI chr20:3,422,448...3,426,420
Ensembl chr20:3,422,461...3,426,371
JBrowse link
G Txlng taxilin gamma multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of TXLNG mRNA CTD PMID:18930950 NCBI chr  X:33,599,643...33,648,525
Ensembl chr  X:33,599,671...33,646,444
JBrowse link
G Ube2c ubiquitin-conjugating enzyme E2C decreases expression EXP trovafloxacin results in decreased expression of UBE2C mRNA CTD PMID:24136188 NCBI chr 3:161,236,971...161,239,371
Ensembl chr 3:161,236,898...161,241,159
JBrowse link
G Ube2i ubiquitin-conjugating enzyme E2I multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of UBE2I mRNA CTD PMID:18930950 NCBI chr10:14,618,615...14,639,274
Ensembl chr10:14,620,531...14,630,151
JBrowse link
G Ubqln1 ubiquilin 1 decreases expression EXP trovafloxacin results in decreased expression of UBQLN1 mRNA CTD PMID:24136188 NCBI chr17:6,840,441...6,878,842
Ensembl chr17:6,840,463...6,878,844
JBrowse link
G Ugt2b17 UDP glucuronosyltransferase family 2 member B17 decreases expression EXP trovafloxacin results in decreased expression of UGT2B17 mRNA CTD PMID:24136188 NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
JBrowse link
G Ulk1 unc-51 like autophagy activating kinase 1 increases expression EXP trovafloxacin results in increased expression of ULK1 mRNA CTD PMID:24136188 NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
JBrowse link
G Umps uridine monophosphate synthetase decreases expression EXP trovafloxacin results in decreased expression of UMPS mRNA CTD PMID:24136188 NCBI chr11:70,034,181...70,044,590
Ensembl chr11:70,034,139...70,044,628
JBrowse link
G Upp1 uridine phosphorylase 1 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of UPP1 mRNA CTD PMID:18930950 NCBI chr14:89,314,234...89,334,060
Ensembl chr14:89,314,176...89,334,276
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of VEGFA mRNA CTD PMID:18930950 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Wbp1l WW domain binding protein 1-like increases expression EXP trovafloxacin results in increased expression of WBP1L mRNA CTD PMID:24136188 NCBI chr 1:266,358,728...266,415,296
Ensembl chr 1:266,358,728...266,415,296
JBrowse link
G Xbp1 X-box binding protein 1 increases expression EXP trovafloxacin results in increased expression of XBP1 mRNA CTD PMID:24136188 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of XDH mRNA CTD PMID:18930950 NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions
decreases expression
ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of XIAP mRNA
[trovafloxacin co-treated with TNF protein] results in decreased expression of XIAP mRNA
trovafloxacin results in decreased expression of XIAP mRNA
CTD PMID:18930950 PMID:32035082 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
G Xpnpep2 X-prolyl aminopeptidase 2 decreases expression EXP trovafloxacin results in decreased expression of XPNPEP2 mRNA CTD PMID:24136188 NCBI chr  X:134,940,656...134,969,874
Ensembl chr  X:134,940,615...134,969,996
JBrowse link
G Xpo1 exportin 1 decreases expression EXP trovafloxacin results in decreased expression of XPO1 mRNA CTD PMID:24136188 NCBI chr14:108,007,421...108,049,088
Ensembl chr14:108,007,724...108,049,660
JBrowse link
G Yars1 tyrosyl-tRNA synthetase 1 decreases expression EXP trovafloxacin results in decreased expression of YARS1 mRNA CTD PMID:24136188 NCBI chr 5:147,375,350...147,403,578
Ensembl chr 5:147,375,350...147,403,571
JBrowse link
G Ypel3 yippee-like 3 increases expression EXP trovafloxacin results in increased expression of YPEL3 mRNA CTD PMID:24136188 NCBI chr 1:198,210,525...198,213,821
Ensembl chr 1:198,210,525...198,213,816
JBrowse link
G Ypel5 yippee-like 5 increases expression EXP trovafloxacin results in increased expression of YPEL5 mRNA CTD PMID:24136188 NCBI chr 6:24,069,351...24,084,758
Ensembl chr 6:24,064,738...24,084,757
JBrowse link
G Zfand5 zinc finger AN1-type containing 5 multiple interactions ISO [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ZFAND5 mRNA CTD PMID:18930950 NCBI chr 1:238,842,506...238,854,030
Ensembl chr 1:238,843,338...238,852,566
JBrowse link
vemurafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA] CTD PMID:29950559 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] CTD PMID:29950559 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of AKT1 mRNA CTD PMID:27169980 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of APAF1 mRNA CTD PMID:27169980 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAD protein CTD PMID:27169980 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAX protein CTD PMID:27169980 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein] CTD PMID:27689874 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2 mRNA CTD PMID:27169980 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2L1 mRNA CTD PMID:27169980 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions ISO [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein] CTD PMID:27689874 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BIRC5 mRNA CTD PMID:27169980 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase decreases activity
affects response to substance
multiple interactions
increases response to substance
ISO Vemurafenib results in decreased activity of BRAF protein; Vemurafenib results in decreased activity of BRAF protein mutant form
BRAF protein affects the susceptibility to Vemurafenib
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased expression of TNFRSF10B protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased expression of CD70 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; BRAF protein affects the reaction [Vemurafenib results in decreased expression of CD70 protein]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; fatostatin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA]
BRAF gene mutant form results in increased susceptibility to vemurafenib; BRAF protein mutant form results in increased susceptibility to vemurafenib
BRAF protein affects the susceptibility to Vemurafenib; BRAF protein mutant form affects the susceptibility to Vemurafenib
CTD PMID:20823850 PMID:21185263 PMID:23237741 PMID:24859340 PMID:26640592 PMID:26751190 PMID:26828592 PMID:26978007 PMID:27222248 PMID:27689874 PMID:29950559 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]] CTD PMID:27222248 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]] CTD PMID:27222248 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion
decreases response to substance
increases expression
ISO vemurafenib results in increased secretion of CCL2 protein
CCL2 protein results in decreased susceptibility to vemurafenib
vemurafenib results in increased expression of CCL2 mRNA
CTD PMID:26684239 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNB1 mRNA CTD PMID:27169980 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]
vemurafenib results in decreased expression of CCND1 protein
CTD PMID:26978007 PMID:27087167 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNE1 mRNA CTD PMID:27169980 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40 protein CTD PMID:27169980 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cd40lg CD40 ligand multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40LG protein CTD PMID:27169980 NCBI chr  X:159,703,703...159,714,886
Ensembl chr  X:159,703,578...159,716,562
JBrowse link
G Cd70 Cd70 molecule decreases expression
multiple interactions
ISO vemurafenib results in decreased expression of CD70 protein
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein; BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein]
CTD PMID:26828592 NCBI chr 9:9,842,585...9,845,728
Ensembl chr 9:9,842,585...9,845,728
JBrowse link
G Cdc25a cell division cycle 25A multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25A mRNA CTD PMID:27169980 NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25C mRNA CTD PMID:27169980 NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO vemurafenib results in decreased expression of CDK4 protein CTD PMID:27087167 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CDKN1B protein CTD PMID:27169980 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CHEK1 mRNA CTD PMID:27169980 NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein] CTD PMID:27222248 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dio3 iodothyronine deiodinase 3 decreases expression ISO vemurafenib results in decreased expression of DIO3 CTD PMID:26825960 NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of E2F1 mRNA CTD PMID:27169980 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G Ehf ets homologous factor multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of EHF mRNA CTD PMID:27169980 NCBI chr 3:93,176,257...93,216,484
Ensembl chr 3:93,178,163...93,216,495
JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein] CTD PMID:27222248 NCBI chr  X:1,287,875...1,304,822
Ensembl chr  X:1,297,099...1,304,822
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein CTD PMID:27222248 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of EZH2 mRNA CTD PMID:27169980 NCBI chr 4:77,284,404...77,347,011
Ensembl chr 4:77,284,404...77,347,011
JBrowse link
G Faslg Fas ligand multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of FASLG protein CTD PMID:27169980 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA] CTD PMID:29950559 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901